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The goal of this needs assessment is to better understand individuals’ drug-use behaviors 
in Nebraska through the lens of treatment providers.  
The results of this study will aid the Drug Overdose Prevention (DOP) program in providing 
training and other resources to treatment centers, focusing prevention efforts, and informing the 
statewide crisis response plan and future studies.  Ultimately, this study will support DOP’s 
efforts to reduce opioid-involved fatal and non-fatal overdoses in Nebraska.
Support and Training for the Evaluation of Programs (STEPs) at the University of Nebraska at 
Omaha is a leader in conducting evaluations of and needs assessments for social service 
programs and policies.  The Nebraska Department of Health and Human Services (DHHS) 
contracted with STEPs in the summer of 2019 to complete a needs assessment that included an 
analysis of secondary data from national and state datasets, a survey of treatment providers, and 
focus groups with treatment providers. 
Community Datasets: Secondary analysis of two datasets: the Treatment 
Episode Data Set (TEDS), and the Nebraska Risk and Protective Factor 
Student Survey (NRPFSS) as a components of the Student Health and Risk 
Prevention Surveillance System (SHARP).
Treatment Provider Surveys: Online survey of administrators in 
residential inpatient treatment facilities and methadone clinics in Nebraska. 
Treatment Provider Focus Groups: Focus groups with medication-assisted 
treatment facilities in Omaha and Lincoln, Nebraska.
Operationalization of “Treatment Providers”
The primary data in this report was collected from substance use treatment facilities.  These 
facilities are most commonly independent of other healthcare facilities (i.e. hospitals or clinics) 
and specialize in the treatment of substance use disorders.  They are generally staffed by 
individuals trained in behavioral health, such as counselors, psychologists, and social workers.  
The focus of treatment tends to be directed at the psychological healing of addiction and trauma 
through modalities such as individual and group therapy delivered by behavioral health 
professionals, with a particular expertise in treating addictions.  While some facilities may 
employ medical staff, such as nurses and psychiatrists, these professionals tend to serve as a 
compliment to psychological treatment, addressing the biological components of addiction and 





The following research questions were developed in collaboration with DHHS and guided 
STEPs’ analyses:
1. What are the demographic characteristics of people in Nebraska who use drugs?
2. What drugs are people in Nebraska using?
3. How do people in Nebraska initiate drug use? 
4. At what point do people in Nebraska seek intervention or treatment?
5. What are the needs of treatment providers?
6. What are the needs of individuals receiving treatment for substance use disorders?
7. What are providers’ perceptions of current DHHS prevention efforts?  
8. What databases do we recommend for further data mining?
1. What are the demographic characteristics of people in Nebraska who use drugs?
Findings from TEDS and SHARP indicate that misuse of substances is disproportionately 
affecting persons of color in Nebraska, especially those identifying as American Indian or Black.  
Most striking, American Indians were significantly over represented in the Nebraska data as 
they accounted for 2% of the Nebraska population, but 7% of substance abuse treatment 
admissions in 2017.
Both Asians and Caucasians were under-represented nationally and in Nebraska.  African 
Americans, however, were over-represented.  According to TEDS, African Americans 
represented 13% of the U.S. population, but 18% of admissions.  In Nebraska, African 
Americans represented 5% of the population, but 11% of admissions.
With respect to gender, males were more frequently represented in both the U.S. (65%) and 
Nebraska (68%) samples.  The most common age category both for the U.S. and Nebraska was 
25-34 years old, representing 35% of the sample.  Overall, Nebraska trends mirrored national 
trends with the exception of the 18-24 year olds with Nebraska showing a 17% admission 
compared to the U.S. admission rate of 13%.
2. What drugs are people in Nebraska using?
According to TEDS, opiates were the most common primary substance identified nationally in 
2017, accounting for 34% of all admissions in 2017.  In Nebraska, opiates accounted for less 
than 4% of all admissions, according to TEDS.  In contrast, according to TEDS, the most 
common substances for Nebraska were alcohol (42% compared to 17% nationally) and 




These findings are consistent with survey results from treatment providers in inpatient 
facilities in Nebraska as they also reported a high prevalence of alcohol and methamphetamine 
as primary substances in addition to marijuana.  Survey results drawn from three of the four 
methadone clinics in Nebraska showed their clients most commonly present with opiate use 
disorder, including prescription pain relievers, heroin, and fentanyl.
According to TEDS, DSM diagnosis data was strikingly different between Nebraska and 
nationally.  Opioid abuse was more common as a diagnosis nationally than in Nebraska (33% 
compared to 4%). Consistent with the primary substances used at admission, DSM diagnoses of 
Alcohol Intoxication and Alcohol Dependence were much higher in Nebraska (20% and 26% 
respectively) than nationally (4% and 19% respectively).  In addition, “other substance abuse” 
was much higher in Nebraska than nationally (26% compared to 8%) and might be related to 
the high incidence of methamphetamine use in Nebraska. Because the TEDS data is focused on 
those who are admitted to treatment, it is quite possible that the true prevalence of opiates and 
other substances is much higher.  
7% of youth responding to the SHARP survey indicated that they had used marijuana in the 
previous 30 days.  Nearly one-fourth of youth who self-reported marijuana use said they started 
at the age of 15 years, with 16% saying they started as 12 years or younger.  A very small 
percentage (4%) of youth reported using prescription drugs without a doctor telling them to 
take them.
Less than 2% of youth in the SHARP survey indicated use of LSD, methamphetamines, 
cocaine/crack, or heroin.
3. How do people in Nebraska initiate drug use? 
According to TEDS and survey findings, first use of alcohol and marijuana most commonly 
occurs during adolescence, and is provided by a friend or relative.  In contrast, these sources 
plus focus group findings show that opioid misuse most commonly begins in adulthood, and 
with a doctor’s prescription.
4. At what point do people in Nebraska seek intervention or treatment?
Individuals are most likely to seek treatment if mandated by a court or other source (i.e. 
employer).  Clients experience many barriers to treatment, especially MAT.  There is a large 
geographic void in access to inpatient treatment facilities, and an even greater void in treatment 
facilities able to prescribe MAT for either opioid misuse or alcohol dependence.  As such, the 
most common barriers to clients accessing treatment are their ability to pay for treatment, and 




According to TEDS, individual or self-referrals account for 43% of referrals.  Trends in referrals 
are very different in Nebraska with only 20% of referrals being from individuals or self-
referrals.  Rather, the largest referral source in Nebraska was the courts/criminal justice system 
(58% compared to 28% nationally).
5. What are the needs of treatment providers?
Very few treatment providers have the capacity to prescribe MAT for OUD or alcohol addiction, 
according to survey results; only slightly more refer clients for MAT. In survey and focus group 
findings, treatment providers reported their greatest needs are for training on evidence-based 
practices (especially related to trauma and MAT), and funding for the workforce to increase 
their capacity to provide MAT, mental health care, and access to rural communities.
They also expressed a need for education for the general public and medical professionals on 
MAT to reduce stigma and unethical prescribing practices.  Additionally, they noted a dearth of 
funding for staff in three distinct areas:  1) Support staff needed to ethically provide MAT; 2) 
Staff to address mental health needs of clients; and 3) Staff to provide services in rural locations 
of Nebraska.  
6. What are the needs of individuals receiving treatment for substance use disorders?
Those seeking a path to recovery need financial support including assistance paying for 
substance treatment (including MAT) as well as transportation and childcare assistance to be 
able to access treatment.  Survey and focus group participants also indicated a need for clients 
to receive more holistic care, especially related to their mental health needs.
7.  What are provider perceptions of current DHHS prevention efforts?  
In survey and focus group findings, treatment providers indicated a disconnect between DHHS 
efforts and their current needs.  On the survey, relatively few providers were informed about 
DHHS’ current prevention efforts; even fewer utilized current resources, despite expressing a 
need for such programming.  They indicated a greater need for funding related to mental health 




8. What databases do we recommend for further data mining?
STEPs recommends continued data mining with the Treatment Episode Data Set (TEDS) and 
the Nebraska Risk and Protective Factor Student Survey (NRPFSS) as part of the Student Health 
and Risk Prevention Surveillance System (SHARP).  In dialogue with DHHS to identify research 
questions, STEPs could dig more deeply into these datasets to answer more specific questions 
about Nebraska.  In addition, data is updated annually or biannually so identified trends need to 
be monitored.
In addition, STEPs anticipates approval to receive the Monitoring the Future (MTF) data.  TEDS 
provides vital data from treatment admissions and discharges, whereas SHARP and MTF 
provide data on youth, which informs youth usage of substances as well as informs prevention 
efforts.
These datasets also show promise in informing substance abuse treatment and prevention in 
Nebraska:
1. National Survey of Substance Abuse Treatment Services (N-SSATS).  This dataset 
originates through an annual survey administered by SAMHSA regarding substance 
use treatment facilities and their clients.
2. National Survey on Drug Use and Health (NSDUH).  The NSDUH is administered by 
SAMHSA and surveys individuals in all 50 states and provides valuable information on 
substance use and mental health. 
3. Behavioral Risk Factor Surveillance System (BRFSS).  The BRFSS is a telephone survey 
which collects data on the health-related risk behaviors, chronic health issues, and 
use of preventative services for United States residents.  According to DHHS, 
beginning in 2018, BRFSS has eight questions regarding substance use.  
Additional Key Findings
According to TEDS, 71% of all discharges are due to treatment completion compared to 41% 
nationally.  
In SHARP results, students generally viewed taking prescription drugs as more wrong and more 
risky than using marijuana.  Students thought their parents were more against their using 
marijuana than prescription drugs.  Students indicated a high likelihood they would go to their 
parents if they needed help with a drug or alcohol problem; they would also likely go to their 
friends.




Treatment Episode Data Set (TEDS): Key Findings
Primary Substance
Nationally, opiates were the most common primary substance identified in 2017, 
accounting for 34% of all admissions in 2017.  In Nebraska, opiates accounted for 
less than 4% of all admissions.  The most common substances for Nebraska were alcohol 
(42% compared to 17% nationally) and methamphetamines (23% compared to 10% 
nationally).  The admissions data indicates alcohol and methamphetamines are the most 
prevalent substance issues Nebraska is facing.  Because TEDS only reports those admitted to 
treatment, the true prevalence of opioid use may be much higher. 
Race
Asians and Caucasians were under-represented both nationally and in Nebraska, 
while Blacks were over-represented.  Nationally, Black individuals represented 18% of 
admissions and 13% of the population; in Nebraska, Black individuals represented 11% of 
admissions and 5% of the population.  Most strikingly though, American Indians were 
significantly over-represented in Nebraska admissions (2% of the Nebraska population 
compared to 7% of admissions).  
Treatment
People admitted in Nebraska were more likely to have no prior treatment 
episodes than U.S. admissions (67% compared to 36% nationally).  
Income and Employment at Admission
Over half of people admitted in Nebraska reported having no income source at 
admission (54%) compared with 35% of U.S. admissions.  However, people admitted 
in Nebraska also reported being employed more frequently and receiving public assistance less 
frequently than U.S. admissions.
Referral
The largest referral source in Nebraska was the courts/criminal justice system (54% 
compared to 28% nationally).
Age at First Use
Most people admitted in Nebraska reported using their primary substance for the 
first time before age 18 (66% compared to 49% nationally).
Discharge and MAT
Discharge data shows that 71% of all discharges were due to treatment completion 
in Nebraska compared to only 41% of U.S. discharges.  Nebraska admissions were 
nearly five times as likely to complete MAT (67% compared to 13% nationally).  Only 4% of 
Nebraska discharges planned to receive MAT at discharge compared to 12% of U.S. discharges.  
Nebraskans are more likely to successfully complete treatment in general and after 
receiving MAT, but utilize MAT less often than U.S. discharges.
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Community Datasets
Treatment Episode Data Set (TEDS)
The Treatment Episode Data Set is a compilation of client information from substance 
use treatment admissions nationwide.  Data from approximately 1.5 million treatment 
admissions across the U,S. are recorded annually through TEDS.  This database 
provides administrative data on admissions to, and discharges from, substance use 
facilities.  This data provides an opportunity to understand admission and discharge 
trends including characteristics associated with admissions and successful discharges.
Admission Demographics
Gender
The majority of treatment admissions were male, 
both nationally and in Nebraska.
*Nebraska Census data based on 5-year population estimates for ages 18 and older in 2017.
Age
The average age for U.S. admissions was 36 years, with 25-39 year-olds accounting for 35% of 
all admissions both nationally and in Nebraska. Nebraska data was consistent with U.S. trends, 
with a slightly higher percentage of admissions for 21-24 year-olds (12% compared to 10%) 














Pregnancy status for 
individuals admitted to 
substance use treatment 
was consistent between U.S. (4% 
pregnant, 96% not pregnant) and 























Nebraska Admissions (n=13,467) U.S. Admissions (n=2,002,847)
Community Datasets
Race/Ethnicity
Racial disproportionality for admissions was observed
across several race types compared to U.S. and Nebraska 
census data. 
Both Asians and Caucasians were under-represented nationally and in 
Nebraska; African Americans were over-represented both in the U.S. 
and in Nebraska.  Most striking though, American Indians were 
significantly over-represented in the Nebraska population (7% of 
Nebraska admissions compared  to 2% of the Nebraska population). 
The majority of Nebraska admissions (92%) indicated they were not 
Hispanic or Latino (n=12,315).  U.S. admissions indicated nearly double 
(14%) those of Hispanic or Latino origin compared to the Nebraska 
percentage (n=2,002,847). 
U.S. Data for 2017









































American Indian Asian/Native Hawaiian/Pacific Islander
Other race/ethnicity
Years of Education at Admission
Compared to the U.S. 
population, individuals 
admitted in Nebraska were 
more likely to have a high school 




Marital Status at Admission
Compared to U.S. admissions, 
individuals admitted in 
Nebraska were more likely to 








married 66% 57% (4,369)
Now 
married 14% 15% (1,169)
Separated 6% 6% (472)
Divorced, 







8 years or less 6% 2% (183)
9-11 years 20% 15% (1,514)
12 years/GED 48% 54% (5,520)
13-15 years 19% 23% (2,392)











8 years or less 9-11 years 12 years (or GED) 13-15 years 16 years or more











Never Married Now Married Separated Divorced, widowed
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Community Datasets
Living Arrangements at Admission
The most striking differences 
within this variable were that 
fewer participants were in a 
dependent living environment and a 







Homeless 17% 19% (1,981)
Dependent 
living 17% 2% (236)
Independent 


























Employment Status at Admission
Fewer individuals who were admitted 
in Nebraska were unemployed (29% 
compared to 38%) and more were 
employed (36% compared to 25%) 














Other 18% 4% (393)















Unemployed 38% 29% (3,242)





Income Source at Admission
Fewer Nebraskans were receiving public assistance at admission compared to the 



















U.S.  Admissions (n=1,794,699)
36% 29% 35%25%
38% 37%
Employed Unemployed Not in Labor
Force
Nebraska Admissions (n=11,261)
U.S.  Admissions (n=1,794,699)
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Community Datasets
Primary Substance Used at Admission
There were striking differences between Nebraska admissions data compared to 
national data with respect to alcohol use, opiate use, and methamphetamine 
use. Nationally, opiate use (34%) was the most common substance identified at 
admission.  In contrast, opiates accounted for less than 4% of all admissions in 
Nebraska. Nebraska's most common substance was alcohol (42%) compared to 17% 
nationally, and methamphetamine (23% compared to 10% nationally).
Age at First Use of Primary Substance
First Use Younger than 18 Years Old
Generally, Nebraska youth appear to use substances much earlier than youth 
nationally.  The majority of admissions in Nebraska (66%) indicated they first used 
the primary substance they received treatment for when they were under the age of 
18 compared to 49% nationally.  Most striking though is that nearly 9% indicated 
they were 11 years or younger in Nebraska and 5% nationally.  (See Appendix A for 

































Nebraska Admissions U.S. Admissions
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Community Datasets
Frequency of Primary Substance Use at Admission
U.S. and Nebraska admissions reported approximately the same frequency of primary 
substance use, with more than 70% of all admissions reporting some use or more at the time of 
their admission to treatment.
Treatment Service Type 
Nebraska admissions receiving detox services (39%) nearly doubled those of U.S. admissions 
(20%). More U.S. admissions (62%) received treatment within an ambulatory service setting 
than did Nebraska admissions (46%). U.S. admissions showed more frequent use of both non-
intensive outpatient treatment (48% U.S. and 40% NE) and significantly higher frequency 
of intensive outpatient treatment (12% U.S. and 6% NE). (See Appendix A for all admission 
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month























Other health care provider
Alcohol/drug use care provider
Individual (includes self-referral)
Court/criminal justice referral/DUI/DWI




The most common referral source nationally was self-referrals (43% U.S. compared 
to 20% in Nebraska) whereas the most common referral source in Nebraska was from the 
criminal justice system (59% in NE compared to 28% nationally).
* There were no admission data for Employer/EAP referrals from Nebraska or nationally.  Admissions data 
showed no referrals to treatment from schools or other educational sources in Nebraska, and less than 1% 
nationally.  
*Detailed criminal justice 
referral is a Supplemental 
Data Set item. Supplemental 
Data Set items are reported at 
each state's option.  Not all 
states report on this item
Criminal Justice Referral Sources
Referrals from the 
criminal justice system 
show that the majority 
come from an "other recognized legal 
entity" (55%) compared to 6% 
nationally.  Given this high 
percentage in the “other,” category it 
is difficult to discern where the 
































In 24 of 49 states and jurisdictions, treatment completion rates were less than 41%.  Nebraska 
data shows that 71% of discharges were due to treatment completion, in sharp contrast to 
national data (41%). Nebraska had a much lower percentage of dropping out of treatment  (9% 



















Nebraska Admissions (n=10,162) U.S. Admissions (n=1,661,207)
Median Length of Stay
There were several differences in the median length of stay for participants who had completed 
treatment.  Overall, outpatient treatments in Nebraska had a much shorter length of stay than 
nationally.  Residential treatment lengths of stay were longer, especially for long-term 


























Nebraska Discharges U.S. Discharges





Planned MAT for Opioid Use at Admission
MAT is not a treatment modality used frequently in Nebraska compared to other states. 















Discharges from Treatment that used MAT 
Nationally nearly 12% of all discharges from treatment were from a MAT treatment service 




Medication Assisted Treatment Discharge: Outpatient
Although not frequently used in Nebraska, when MAT is used there appears to be good success 
with the treatment.  When used in an outpatient setting, treatment was completed 67% of the 













Transferred to another treatment program or
facility
Terminated facility
Dropped out of treatment
Treatment completed












Transferred to another treatment program or facility
Terminated facility
Dropped out of treatment
Treatment completed
U.S. discharges (n=26,249) NE discharges (n=86)
Medication-Assisted Treatment Discharge: Detoxification
In contrast to the outpatient success with MAT, only 29% of people admitted in Nebraska 
successfully completed MAT when used in detox settings (compared to 44% in the U.S.) and 





Arrests 30 Days Prior to Discharge
Number of arrests within the past 30 days among treatment discharges were consistent across 
national and Nebraska data.
Number of Previous Treatment Episodes
The majority of U.S. admissions had received substance use treatment previously (64%) 
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times, 1%









Self-Help Group Attendance Prior to Discharge
There appears to be a greater frequency in self-help group attendance by Nebraskans prior to 












Some attendance, frequency is unknown
8-30 times in the past month
4-7 times in the past month
1-3 times in the past month
No attendance
Nebraska Admissions U.S. Admissions
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Community Datasets
Treatment Episode Data Set (TEDS): Limitations
1. Representativeness
TEDS reports information on admissions to treatment facilities, not individuals.  
Someone who is admitted to treatment twice in one year, therefore, may represent 
two data points.  A client transferring from one service type to another (such as inpatient to 
outpatient) may be recorded as an additional admission depending on the facility, even if the 
services were provided within the span of one treatment episode.  
2. Disproportionate Representation from Urban Areas
Most substance use treatment facilities in Nebraska are located within Douglas and 
Lancaster counties.  TEDS data may disproportionately represent an urban 
demographic due to their proximity to treatment facilities and subsequent ease of access to 
treatment.
3. Small Sample Size
The sample size of Nebraska admissions and discharges was significantly smaller than U.S. 
admissions.  The difference in sample size is important to consider when looking at percentages 
throughout this report.
4. Incomplete Data on Admissions
Not all treatment admissions are captured by TEDS.  While TEDS collects data from facilities 
receiving state funds, private treatment facilities and those operated by hospitals or correctional 
systems may not be included. 
5. State Variation
Some states vary on their data collection processes, which limits the U.S. admissions data 
available.  Other differences between states, such as the availability of MAT or the states’ 




1. Target American Indian and Black youth in alcohol- and methamphetamine-focused 
prevention efforts.
2. Discover how beds are being allotted, whether enough beds are available to meet the need, 
and characteristics and experiences of individuals on waiting lists.
3. Increase implementation of MAT as it appears to be successful in outpatient settings.
4. Provide treatment providers evidence-based and culturally appropriate tools to better serve 
racially diverse populations.
5. Examine TEDS data:
a. Longitudinally to identify trends in primary substance use, treatment modalities, and 
treatment outcomes by demographic characteristics. 
b. To analyze nearby states’ primary substance use over time to determine possible trends.  
Assess those characteristic differences between Nebraska and other states that may affect 
Nebraska’s primary substance use patterns in the future.
c. To determine the risk factors influencing the higher rates of substance use among 
American Indians and Black or African American individuals.
d. Through the lens of survey and focus groups results.
6. Utilize data sources other than TEDS to:
a. Determine the characteristics of those individuals not receiving treatment and the services 
needed to support their access to treatment.
b. Determine the untreated prevalence of opioid use and misuse in Nebraska. 
c. Discover protective factors for American Indians and Black individuals, and utilize these 
factors for improving prevention and treatment efforts targeted at these populations.
d. Further assess how the urban-rural divide influences the initiation of substance use and 
treatment need to support future prevention and intervention efforts.
e. Examine income sources of Nebraskans (TEDS shows 54% of admissions have no income).
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Community Datasets
Student Health and Risk Prevention Surveillance System (SHARP)
Since 2010, the SHARP Surveillance System has encompassed three school-based surveys in 
Nebraska, including the Nebraska Risk and Protective Factor Student Survey (NRPFSS). The 
NRPFSS includes a census of students in participating public and non-public high school in 8th, 
10th, and 12th grades.  All Nebraska schools are invited to participate and all students in eligible 
grades are asked to complete the survey.  For those schools who choose to participate, a school 
district report and optional individual school report may be provided at no cost. 
Key Findings
1. Most students perceived illegal drug use and prescription drug misuse as wrong.
2. 16% of students self-reported as having used marijuana at some point in their life, and 7% 
reported that they had used in the past 30 days.  Nearly half (42%) of those who had used 
marijuana in the past 30 days, reported they had used it 10 or more times. 
3. One-fourth of students who self-reported as having used marijuana said they started at age 
15.
4. Over one-fourth of students said it is relatively easy to get marijuana. 
5. Although the number of responses from students who self-identified as American Indian, 
Alaska Native, and Pacific Islander was very low compared to students in other racial 
groups, their responses indicated that these minority race groups have unique perceptions 
and needs.  They are less likely to view illegal drug use or prescription drug misuse as 
problematic, and they are more likely to have used illegal drugs or to have misused 
prescription drugs than students in other racial groups.
6. Students identifying as Black reported a higher use of marijuana than White or Asian. 
7. Students generally viewed taking prescription drugs as more wrong and more risky than 
using marijuana. 
8. Students indicated a high likelihood they would go to their parents if they needed help with 
a drug or alcohol problem; they would also likely go to their friends.
9. Over one-third of students did not perceive prescription drug misuse as a great risk.
10. Drug use perceptions and behaviors are similar for male and female students.
11. Students self-reported a very low rate of misusing prescription drugs or using LSD, 
cocaine/crack, methamphetamines, heroin, or synthetic drugs.  They also reported a low 
likelihood of using inhalants.
12. If students thought they needed help for a drug or alcohol problem, most would turn first 
to parents or caregivers and many would turn to friends. The 12- and 19-year-old students 











































Student Health and Risk Prevention Surveillance System (SHARP)
Sample Description
In 2018, 24,847 students completed the Nebraska Risk and Protective Factor Student 
Survey (NRPFSS) in Nebraska.  Most students were in 8th (42%), 10th (30%), or 12th 
(26%) grades, which correlates to about 13, 15, and 17 years old.  Over two-thirds of 
students (84%) self-reported as White.
Age (n=24,825) Students most often identified as being 13, 15, or 17 years old.  
Gender (n=24,781)
Half of students identified as female 
and the other half identified as male.
Grade (n=24,785)
Students most often identified as being in 
the 8th, 10th, or 12th grade, with nearly 
half of respondents being in 8th grade.
Race/Ethnicity
Most students reported “White” as at least one of 
their racial identities.  One in five students 
identified themselves as Hispanic or Latino.  
(According to the U.S. census, 86-87% of youth 
ages 10-19 years old in Nebraska are white.)
Students were able to identify more than one racial 
category.  The number shown is representative of the 
number of responses each race/ethnicity category 
























Perception of Illegal Drug Use (n= 24,484)
When asked, "How wrong is it to use LSD, cocaine, amphetamines, or another illegal 
drug," 88% of students responded “very wrong.”  
88% 9% 2%1%













Very Wrong Wrong A bit wrong Not wrong
Perception of Illegal Drug Use by Race/Ethnicity
Slightly fewer students who identified as Pacific Islander and/or Alaska Native students thought 









































Very Wrong Wrong A little bit wrong Not wrong at all
Perception of Illegal Drug Use by Gender




Marijuana Use: Lifetime and Past 30 Days
16% of students (3,765) self-reported using marijuana at some point in their 
lifetime, and 7% (1,743) reported using marijuana in the past 30 days.  
Marijuana Use by Gender (male, n=12,045; female, n=11,932)
Nearly identical proportions of male and female students reported using marijuana.
Frequency of Use in the Past 30 Days (n=3,792)
Of those who reported using marijuana in the past 30 days, 34% said they had used 
marijuana 1 or 2 times, 23% said 3 to 9 times, and nearly half (42%) said they had 
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Marijuana Use by Race/Ethnicity
Although there were much fewer students represented, students in these racial 
groups reported much higher rates of marijuana use: American Indians (28%), Black 
(24%), Pacific Islander (24%), and Alaska Native (23%).
Age of First Marijuana Use (n=3,565)
Of the 3,565 students who self-reported as using marijuana, nearly one-fourth started at the 
age of 15.  A small number (16%) started at 12 years or younger.
Ease of Access to Marijuana (n=23,434)
Over one fourth of all students (28%) responded it is "sort of" or "very" easy to get 
marijuana.  
15%



































Perception of Marijuana Use (n=24,384)











 How wrong do


















































12 years old or
younger (n=80)
Very Wrong Wrong A bit wrong Not wrong
Perceptions of Marijuana Use by Age
More students 14 years and younger felt marijuana use was “very wrong” than did older 




Perception of Marijuana Use by Gender





















































Very Wrong Wrong A bit wrong Not wrong
Perception of Marijuana Use by Race/Ethnicity
Students of various races responded similarly, although somewhat fewer Black, American 









How much do you think people
risk harming themselves if they





Youth’s Perceptions of How Parents, Adults, and Friends View Marijuana Use
While 65% of students thought using marijuana was "very wrong," many more 
indicated their parents viewed marijuana use as "very wrong" (87%), and slightly 
more thought the adults in their neighborhood would as well (70%).  Students' 
perceived that just over half of their friends saw smoking marijuana as "very wrong" (57%).
Perception of Marijuana Use by Peers in Past 30 Days (n=24,352)

















Very wrong Wrong A bit wrong Not wrong
Perceived Risk of Marijuana Use (n=24,310)
One-fourth of students (25%) assessed the risk of smoking marijuana as a slight risk 










Half to most (51-70%)







Lifetime Prescription Drug Misuse by Gender (n=24,065)
Male and female students reported approximately the same rate of misuse.
Lifetime Prescription Drug Misuse by Race (n=24,065)














Black White Asian Other
Prescription Drug Misuse: Lifetime and Past 30 Days
1,076 (4%) of students reported using prescription drugs (such as Valium, Xanax, 
Ritalin, Adderall, OxyContin, Vicodin, or Percocet) without a doctor’s instructions to 





0 times 1-2 times 3-9 times 10 or more
times




Request to Borrow or Buy Prescription 
Medication (n=11,649)
670 students (5%) indicated someone else 
asked to borrow or buy some of their 
medication the last time a doctor 
prescribed them a pain medication.
Higher Use than Directed by Prescriber 
(n=12,187)
722 students (6%) reported using 
prescription pain medications more 






Ease of Access to Prescription Drugs (n=23,396)








How easy would it be













 How wrong is it for
someone your age to
use prescription drugs?
Perception of Prescription Drug Misuse (n=24,377)
Over three-fourths of students overall indicated their belief that someone their age 
misusing prescription drugs without a doctor telling them to was "very wrong."
Risk of Harm in Misuse of Prescription Drugs (n=24,378)
Just over one-third of students (35%) assessed the risk of misusing prescription 









How much do people
risk harming









































12 years or younger (n=79)




Perception of Prescription Drug Misuse by Age (n=24,377)
The majority of students perceived the misuse of prescription drugs as “very wrong” 
regardless of age.
Perceptions of Prescription Drug Misuse by Race/Ethnicity (n=24,377)














































Perceptions of Prescription Drug Misuse of Parents and Friends 
While nearly all (95%) of students thought misusing prescription drugs was "very 
wrong“ or “wrong,” 98% thought their parents shared that view.  Students' perceived 














Very Wrong Wrong A bit wrong Not wrong
Perceptions of Prescription Drug Misuse by Gender (n=24,377)














Very wrong Wrong A little bit wrong Not wrong at all
Perceptions of Marijuana Use Compared to Prescription Drug Misuse
Students generally viewed taking prescription drugs as more wrong and more risky than using 




LSD and Other Psychedelic Drugs
Lifetime LSD or Other Psychedelic Drug Use by Race (n=24,007)
Students who identified as American Indian (4.6%) and/or Pacific Islander (3.6%) reported a 











Black White Asian American
Indian
Other
Lifetime LSD or Other Psychedelic Drug Use (n=24,007)
579 (2.7%) of students reported using LSD or other psychedelic drugs in the past 30 
days.
98% Nearly 100% of students reported never using LSD or other psychedelic drug. 
Cocaine and Crack
Lifetime Cocaine/Crack Use (n=23,958)
246 (1%) of students reported using cocaine or crack.
Lifetime Cocaine/Crack Use by Race/Ethnicity (n=23,958)
Students who identified as American Indian (2.3%) reported a slightly higher rate of 
cocaine/crack.
0.9%









99% Nearly 100% of students reported never using cocaine or crack. 




Lifetime Methamphetamine Use (n= 24,062)
118 (less than 1%) of students reported using methamphetamines, which included 
speed, crank, crystal meth, or ice.
Lifetime Methamphetamine Use by Race/Ethnicity (n=24,062)
Students who identified as American Indian (1.7%) and/or Pacific Islander (1.6%) reported a 
slightly higher rate of methamphetamine use.
0.5%







Black Asian White Other
100% Nearly 100% of students reported never using methamphetamine drugs. 
Lifetime Heroin Use (n= 24,086)
44 (less than 1%) of students reported using heroin, which included smack, junk, or 
China White.
Lifetime Heroin Use by Race/Ethnicity (n=24,086)
Students who identified as American Indian and/or Pacific Islander reported a slightly higher 
rate of heroin use.






Black Asian White American
Indian
Other
100% Nearly 100% of students reported never using heroin. 
Heroin




Lifetime Synthetic Drug Use (n= 24,097)
236 (0.01%) of students reported using synthetic drugs, which included man-made 
drugs such as K2, Bath Salts, Spice, fake weed, King Kong, Yucatan Fire, or Skunk.
Lifetime Synthetic Drug Use by Race/Ethnicity (n=24,097)
Students who identified as American Indian reported a slightly higher rate of use.
0.8%









100% Nearly 100% of students reported never using synthetic drugs. 
Inhalants
Lifetime Inhalant Use (n=24,121)
957 (4%) of students reported using inhalants like sniffed glue, breathed the contents 
of an aerosol spray can, or inhaled other gases or sprays in order to get high.
Lifetime Inhalant Use by Race/Ethnicity (n=24,121)













Black Asian White Other
96% Nearly 100% of students reported never using inhalants. 























First Contact Person in Seeking Help (n=23,617)
When asked, "If you had a drug or alcohol problem and needed help, who is the 
FIRST person you would go to," over one-third of students (40%) said parents or 
caregivers.  One-fourth of students said they would go to friends, with fewer going to counselors 

















































Parents or caregivers Friends
Counselor or adult in school Counselor or adult outside school
Wouldn't to to anyone
First Contact Person in Seeking Help by Gender (n=23,617)
Students of all races were likely to turn to their parents, except Pacific Islanders who had a 




First Contact Person in Seeking Help by Gender (n=23,617)














Parents or caregivers Friends
Counselor or adult in school Counselor or adult outside school

























































Parents or caregivers Friends
Counselor or adult in school Counselor or adult outside school
Wouldn't to to anyone
First Contact Person in Seeking Help by Age (n=23,617)
Students ages 14 years and under had a higher likelihood of turning to parents, and 17- and 18-
year-old students had a higher likelihood of turning to friends.  12-year-old students were more 
likely to turn to another adult in the school, and 19-year-old students were much more likely to 




Anti-Alcohol and Anti-Drug Messages (n=23,175)
74% Three-fourths of students (74%) recalled seeing or hearing an anti-alcohol or anti-drug message in the past 12 months.
Honesty in Survey Completion (n=23,562)
97% of students indicated they were "very honest" or “honest most of the time” in responding 
to survey items.
Very or most of 
the time, 97%
Some of the time 
or once in a while, 
3%
 How honest were you




1. Data is for Nebraska as a whole and cannot be applied to any specific geographic area of 
Nebraska, including rural or urban areas.  School-identifying information is not available.
2. Responses were based on students self-report and are only as valid as students were able 
and willing to respond accurately.  Given the sensitivity and stigma of topics in the survey, 
students may have over- or under-reported their drug use.
3. Nearly half of responses were from students in 8th grade, so results are most 
representative of that age group.
4. Parental consent is required for student participation in the survey.  Data was not 
collected from students from whom parental consent was not received. 
5. Results are drawn from a random sample of students in public and non-public schools in 
Nebraska.  Students being homeschooled are not sampled.  Also not represented are 
those students who may have been absent from school on the day the survey was 
administered.
Recommendations
1. Direct prevention and intervention services at students of all ages and genders, with 
additional attention to students who identify as African American, American Indian, 
Alaska Native, or Pacific Islander. 
2. Provide education and materials to parents for use in talking with their children about 
drug use. 
3. Identify curriculum and messaging for schools to aid students in talking with their peers 
about healthy behaviors in regards to drug use. 
4. Continue to direct social media and other sources of messaging at students on drug use 
prevention and intervention.
Monitoring the Future (MTF)
Since 1975, the annual Monitoring the Future (MTF) survey has tracked national substance use 
among U.S. adolescents.  Each year, MTF surveys a random sample of approximately 50,000 
students in 8th, 10th, and 12th grades in 420 public and non-public schools.  A small sample of 
high school seniors is also chosen to participate in longitudinal, follow-up surveys for multiple 
years after graduating from high school.  MTF is conducted by the University of Michigan and 
funded by the National Institute on Drug Abuse. 
44
Community Datasets
Students chosen to participate in the MTF survey are asked about 
their drug-use behaviors in the past month, the past year, and 
over their lifetime.  Survey items regarding drug-use prevention 
programming and their attitudes around substance use may be useful 
variables for this study. 
The Monitoring the Future data is a nationally based dataset housed by the 
Inter-University Consortium for Political and Social Research (ICPSR) at the 
University of Michigan.  Since the information is not publicly available, STEPs 
has not yet been able to ascertain any Nebraska-specific data or findings. 
Several steps and formal reviews are required to obtain access to the Monitoring 
the Future data.  First, individuals applying for data access must be preapproved 
through their university’s institutional review board.  STEPs prepared an 
application, submitted it to the institutional review board at the University of 
Nebraska Medical Center via their electronic portal system, and received the 
needed approval.  
Second, individuals are required to submit the IRB approval along with a specific 
data request demonstrating prior experience with confidential data sources.  
STEPs submitted this data request and accompanying documentation and is 
currently awaiting ICPSR’s review and final determination on access to the 






Type of Treatment: While only three methadone providers responded to the survey, their 
responses regarding all drug use behaviors were starkly different than inpatient providers.  
Those seeking treatment from methadone clinics varied significantly from those seeking 
treatment in other inpatient facilities. 
Medication-Assisted Treatment (MAT)
Few inpatient facilities indicated an ability to prescribe for MAT, especially 
for those medications indicated exclusively for opioid use disorder.  Only half 
of inpatient providers referred for any opioid-indicated MAT.  Both the ability to 
prescribe and reports of referrals occurred more often among providers located in the 
eastern third of Nebraska.  
However, there was an inverse relationship between providers with Opioid Use Disorder 
(OUD) beds in Lancaster County, and their reports of prescribing or referring for MAT.  Despite 
the majority of beds for OUD being in Lancaster county, these facilities seemed to 
prescribe or refer for OUD-related MAT less often than other providers. Across providers, 
buprenorphine is more commonly referred or prescribed than methadone.  Naltrexone 
(indicated for the treatment of both opioid and alcohol use disorders) is the pharmacotherapy 
most inpatient providers refer out for or prescribe.  Many needs arose for both clients and 
providers related to MAT, as discussed on the following page.
Methadone Clinics
Methadone providers identified that 100% of their clients had an opioid use 
disorder and were using a combination of prescription pain relievers, 
heroin, and fentanyl.  Methadone providers reported that the first substance 
misused by their clients was prescription pain relievers obtained from a 
doctor, often as adults.  Methadone providers did not report other substances 
used by their clients.
Inpatient Facilities
In contrast to methadone providers, inpatient providers reported their clients 
had a higher usage of methamphetamines, often paired in combination with 
alcohol and marijuana. Inpatient providers identified relatively low use of 
opioids in their clients.  According to inpatient providers, their clients’ first 
misused substance was typically alcohol, obtained from a friend or family 





Medication-Assisted Treatment: Providers indicated a need for financial 
assistance to be able to give clients MAT.  Some providers also identified the 
stigma around MAT as a barrier to clients and suggested that public 
education around MAT would be a potentially helpful prevention effort.
Treatment Access: The geographic location of current inpatient treatment 
facilities leaves a huge gap in service in terms of access to treatment and MAT, 
especially in central and southwestern Nebraska.  Individuals in need of 
inpatient treatment may have to travel up to 3 hours to locate the nearest 
inpatient treatment facility.  Additionally, the only methadone treatment 
facilities are in Lincoln and Omaha, leaving the central and western sections 
of Nebraska completely devoid of this vital treatment. 
Children: In multiple questions, providers identified a lack of long-term 
childcare and the fear of children being removed from the home as some of 
the most common external factors that prevent clients from seeking 
treatment.  Some providers reported a need for residential treatment programs 
that incorporate dependent children to increase access to treatment and address 
generational substance use.
Financial Barriers: Some providers identified their clients’ finances as a 
significant barrier to both entering and completing treatment.  According to 
providers, financial concerns impact a myriad of factors related to treatment 
access, including the ability to afford residential inpatient treatment, MAT, long-
term childcare, and transportation to treatment.
Treatment Provider Needs
Training on Evidence-Based Practices: When asked about helpful training 
received in the past and interesting training topics for the future, providers 
consistently identified evidence-based practices as the most common need.  
Providers specifically demonstrated an interest in trauma-informed care
(especially evidence-based trauma treatments), motivational interviewing, and 
MAT.
Funding: Providers indicated a need for additional funding for a variety of 
services, particularly to create or expand the workforce to better meet the demand 





Disconnect between Prevention and Providers: Although there are many 
prevention efforts that have the potential to directly assist individuals currently 
seeking treatment, and those that provide substance abuse treatment for them, 
relatively few providers indicated a knowledge or utilization of current 
efforts. Further illustrating this disconnect, sometimes providers listed the need 
for a service that already exists.  For example, several providers indicated a need 
for financial assistance to clients accessing buprenorphine and an increase in MAT 
workforce capacity, despite these being resources that currently exist.  
Most Helpful Prevention Efforts: In addition to providers supporting public 
education concerning MAT, medically based prevention efforts were identified as 
being among the most helpful or current efforts.  Providers indicated prescriber 
education and addiction screening at primary care facilities as being particularly 
helpful.  Educational outreach, especially to middle school age children, was 




Treatment Provider Survey Purpose
The purpose of the quantitative survey with treatment providers was to discover clients’ drug 
use behaviors, providers’ needs, and providers’ perceptions of DHHS prevention efforts.  The 
goal of this needs assessment was to better understand individuals’ drug use behaviors through 
the lens of treatment providers.
Survey Administration
Between June 26 and July 23, 2019, STEPs administered the survey by sending a Qualtrics link 
to one provider at each of the 25 inpatient substance use treatment facilities licensed by 
Nebraska DHHS, in addition to the 4 methadone clinics in Nebraska.  STEPs received 20 total 
responses.  Respondents’ identities were not requested.  
Program Type
Providers most often indicated their program to be 
residential inpatient treatment, either long-term (40%) 
or short-term treatment (n=19, 40%).
Rural vs. Urban
Based on the counties indicated by providers, most of the 
facilities were located in urban counties (Douglas and 
Lancaster counties) (n=19). 
Provider Comparisons
For certain questions, the 
responses of inpatient facilities 
and methadone clinics were 
significantly different and are thus 
reported separately to illustrate 
the distinction.  
It is important to keep in mind 
three of the four methadone 
clinics in Nebraska responded to 
the survey.  The methadone clinic 
sample size, therefore, is 
significantly smaller than the 
inpatient facility sample size.  
Evaluators examined any potential 
disparities between urban 
(Lancaster and Douglas counties) 
and rural providers (all other 
counties).  However,  there was 
generally little distinction between 
the two groups.
16 Inpatient Facilities
• 8 long-term (more than 30 days)








Facilities by County 
The treatment provider survey was sent to all 29 
licensed inpatient substance misuse facilities in 
10 counties.  20 providers from six counties 
responded to the survey.  Most of the respondents 
were in Douglas or Lancaster counties, both of 
which are in the eastern part of Nebraska.  The 
survey results, therefore, are a more accurate 
reflection of treatment providers in urban areas 
in the eastern third of Nebraska.
Map note: The first number below the county name 
indicates the number of providers who responded.  
The second number indicates how many providers 
were sent a survey (all licensed providers).  This 








































Number of licensed 
facilities sent a survey
Methadone Clinics
All the methadone clinics are in either Douglas 










Role in Facility 
Approximately half of 
respondents serve as the 
program administrator, director, 
or manager (n=19, 55%) at their facility.  Of 
the two respondents who chose “other,” one 
indicated they serve as the “director of 





For the remainder of this section, the survey question will be stated in full inside the box, followed by 
the relevant analysis. 
Intravenous (IV) Drug Use
Thinking about clients served in your program over the past year, approximately what PERCENT 
of these clients were considered IV drug users? 









Inpatient Facilities (n=15) Methadone Clinics (n=3)
Inpatient facilities reported a median of 30% 
of clients who used drugs intravenously in 
the past year.  Five inpatient providers 
reported at least half of their clients used IV 
drugs.  Fewer inpatient providers indicated 
their clients using IV drugs in comparison to 
methadone clinics.
Methadone clinics reported a median of 
72% of clients who used drugs 
intravenously in the past year.  Two of the 
three methadone providers reported their 
clients used IV drugs.  





Percent of clients who were IV drug users
Total Opioid Use Disorder (OUD) Beds 
Six inpatient facilities reported having OUD beds.  115 OUD beds were reported 
across the six facilities, the majority of which were reported in Lancaster county.  Survey results 
indicated both a lack of treatment providers and OUD beds in the southwestern part of 




Methadone providers (n=3) reported a capacity 
to serve 50 OUD clients in addition to those 




Substances Used by Clients
Thinking about clients served in your program over the past year, approximately 
what PERCENT of these clients have presented needing treatment for the misuse of:
Note: Providers responded to each substance independently.  Thus, since many clients present 
with multiple substance use, the cumulative percentage generally exceeded 100%. 
Inpatient providers indicated a higher 
average percent of clients presenting for 
treatment related to methamphetamines 
(66%,), followed by alcohol (65%), and 
marijuana (55%).  Fewer inpatient providers 
indicated their clients sought treatment for 
opioids, benzodiazepines, or cocaine 
compared to methadone providers.
All three methadone providers indicated 
100% of their clients use prescription pain 
relievers.  Most methadone providers also 
indicated their clients commonly use heroin 
(72%) and fentanyl (57%).  Methadone 
providers indicated nearly half of clients use 
marijuana (48%) and methamphetamines 
(40%).


































Inpatient Facility Outpatient Clinic
Percent of Clients Needing Treatment by Substance
Relatively few inpatient providers reported their clients use opioids in comparison to 




Primary Drug of Choice
Thinking about clients served in your program over the past year, what have been their most 
common primary drugs of choice?  (select all that apply)
What PERCENT of your clients have an opioid use disorder (prescription pain relievers, 
fentanyl, heroin)?
Percent of Clients with Opioid Use Disorder (OUD)
Inpatient Facilities (n=15) Methadone Clinics (n=3)
Most respondents (68%) listed 
methamphetamines as one of the most 
common primary drugs of choice.  Alcohol 
(64%) and marijuana (45%) were also 
common primary drugs listed.  This is 
consistent with the common substances 
reported by inpatient providers on the 
previous page.
100%
All three methadone clinics 
reported their clients’ primary 
drugs of choice in the past year 
were “prescription pain relievers, 

















Percent of clients by primary drug of choice
Inpatient Facilities (n=15) Methadone Clinics (n=3)
Providers generally reported less than one-
third of clients (23%) have an OUD. 100%
All three methadone clinics 








Primary Drug of Choice
Thinking about clients served in your program over the past year, what have been their most 
common primary drugs of choice? (select all that apply)
What PERCENT of your clients have an opioid use disorder (prescription pain relievers, 
fentanyl, heroin)?
Percent of Clients with Opioids Use Disorder (OUD)
Inpatient Facilities (n=15) Methadone Clinics (n=3)
Most respondents (68%) listed 
methamphetamines as one of the 
most common primary drugs of 
choice.  Alcohol (64%) and marijuana 
(45%) were also common primary drugs 
listed.  This is consistent with the common 
substances reported by inpatient providers 
on the previous page.
100%
All three methadone clinics 
reported their clients’ primary 
drugs of choice in the past year 


















Percent of clients by primary drug of choice
Inpatient Facilities (n=15) Methadone Clinics (n=3)
Providers generally reported less 
than one-third of clients (23%) 
have an OUD.
100%
All three methadone clinics 








Clients Who Are Polysubstance Users
In the past year, what PERCENT of clients in your program were dependent on multiple 
substances? (polysubstance or multiple substance dependent)
Inpatient Facilities (n=15) Methadone Clinics (n=3)
Providers reported a median 80% of 
clients as dependent on multiple 
substances.   14 of the 15 inpatient 
providers indicated over half their 
clients are polysubstance users. 
Providers reported a median 40% of clients 
as dependent on multiple substances.   Two 
methadone providers indicated 40% of 





Percent of clients who are 
polysubstance users





Most Common Polysubstance Drug Pairings
We would like to know about trends you are seeing in the use of multiple substances.  For each 
of the primary substances listed below, please indicate the drug or drugs that you commonly 
see paired with each substance.  
Inpatient Facilities (n=15) Methadone Clinics (n=2)
Inpatient providers consistently 
indicated the pairing of 
methamphetamines, marijuana, 
and alcohol.  Providers indicated 
methamphetamines as the primary substance 
paired with alcohol and marijuana more than 
any other combination.  Fewer providers 
indicated that when prescription pain relievers 
were the primary substance, marijuana, 
methamphetamines, and alcohol were paired 
with prescription pain relievers.
Methadone providers 
indicated heroin, fentanyl, 
and prescription pain 
relievers as being primary substances 
paired with other drugs. Both 
methadone providers indicated heroin and 
prescription pain relievers being paired 
with methamphetamines and 
benzodiazepines.  One methadone 
provider indicated fentanyl as a primary 
substance, paired with 
methamphetamines and benzodiazepines.













Some providers reported pairing
Most providers reported pairing
Primary drug of choice and paired drug
Paired drug only
The full results are provided in a 
table in Appendix C.
Treatment Provider Survey
Drug Use Initiation
Most Common Substance First Misused
What is your perception of the most common substance that is first misused by your clients? 
Age at First Misuse





Inpatient Facilities (n=14) Methadone Clinics (n=2)
Most inpatient providers indicated alcohol 
was the first substance misused by clients 
(n=11, 79%).  A few inpatient providers also 





Methadone providers reported 
prescription pain relievers were the first 


















One methadone provider indicated most 
clients in their program began misusing at 
age 19 or older (n=1).  (Only one 
methadone provider answered this 
question.)  
Most inpatient providers 
indicated their clients first 
misused a substance at age 14 or 
younger (n=12).  A few inpatient providers 
also indicated their clients began using 




















Most Common Reason for First Misuse
In your opinion, what are the most common reasons for clients’ first substance misuse? 
(check all that apply)
Response Options
• Peers encouraged them to
• Experiment/see what it’s like
• Feel good/get high 
• Help with feelings or emotions 
• Parents or other family members encouraged them to
• Pain relief
• Relax or relieve tension 
• Help with sleep 
• Help be alert or stay awake
• Help study
• Help concentrate
• Help lose weight
• Unknown
• Other _____________
Inpatient Facilities (n=15) Methadone Clinics (n=1)
Only one methadone provider responded 
to this question.  The methadone provider 
was the only respondent who indicated 
“pain relief,” help with sleep, and relax or 
relieve tension as reasons for clients’ first 
substance misuse.  This methadone 
provider also indicated clients first misuse 
substances to “feel good/get high” and 
“help with feelings or emotions.” 
Top Five Reasons for First Misuse (n=16)
Inpatient providers most often indicated clients first misused substances due to 
peers’ encouragement.
Providers indicated the top two most 
common reasons for their clients’ first 
substance misuse was “peer pressure” or 
the desire to “experiment/see what it’s 
like.”  No providers indicated clients’ first 
misuse was due to help being alert or 
staying awake, studying, concentrating, or 




Source of First Misuse
Where did clients most commonly get the substance they first misused?
Response Options
• Got from friend or relative for free 
• Took from friend or relative without asking 
• Bought from friend or relative 
• Got from a doctor
• Stole from doctor’s office, clinic, hospital, or pharmacy 
According to most inpatient providers, 
clients most commonly obtained their first 
misused substance “from a friend or 
relative for free.”  All inpatient providers 
indicated their clients’ source was a friend 
or relative, whether the substance was 
given for free, purchased, or stolen. 
Clients’ Sources of First Misuse
Most inpatient providers indicated their clients first misused substance was 
obtained “from a friend or relative for free” (n=15).
• Bought from drug dealer or 
other stranger 
• Other ___________
Inpatient Facilities (n=15) Methadone Clinics (n=1)
One methadone provider responded to this 
item indicating the source of their clients’ 




From a friend or
relative for free
Took from friend or
relative without asking
Bought from a friend
or relative
No providers indicated the source of their 





Respondents indicated whether they 1) prescribe, 2) refer, or 3) neither prescribe nor 
refer for a variety of different medications for substance abuse treatment.  Providers 
indicated this for all major pharmacotherapies indicated for both opioid and alcohol 
dependency as well as a general statement related to medications for psychiatric disorders.  17 
providers responded to questions surrounding MAT; 18 providers responded to questions 
regarding medications for psychiatric disorders.
Overall, buprenorphine, naltrexone, and acamprosate were favored as pharmacotherapies 
over methadone and disulfiram.  Significant differences, however, emerged based on provider 




















Pharmacotherapy Involvement by Inpatient Facilities
Target Addiction MAT Medication
Opioid Use Disorder Methadone 
Buprenorphine
Opioid Use Disorder and 
Alcohol Use Disorder
Naltrexone
Alcohol Use Disorder Acamprosate
Disulfiram
Pharmacotherapy Treatment Use
The table to the right outlines the MAT 
medications and the corresponding 
substance dependencies they treat.
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Treatment Provider Survey
Medication-Assisted Treatment for Opioid Use Disorder
Methadone 
Only about half of inpatient providers (n=9, 53%) reported providing referrals for methadone, 
making it the least commonly referred pharmacotherapy.
There seemed to be a disparity related to methadone referrals based on geographic 
location.  Only two rural inpatient providers, located in Madison and Sheridan 
counties, indicated referring for methadone treatment.  Additionally, only two 
facilities in Lancaster county indicated they refer for methadone treatment, despite having a 








Douglas Lancaster Madison Hall Holt Sheridan
Neither Refer
Methadone Clinics
As expected, only methadone 
clinics reported prescribing 
methadone (n=3).  One 
methadone clinic also reported 
prescribing buprenorphine, and 
one reported referring for 
psychiatric medications.  
Inpatient Facility Methadone Referral by County (n=17)
Given that respondents also indicated elsewhere on the 
survey that a relatively small number of their clients need 
treatment for OUD, and methadone clinics are often located 
far from the inpatient treatment facility (with the exception 
of the Lancaster county respondents), it is unclear if the 
lack of methadone referral is due to a lack of client need for 
methadone treatment, lack of client access to methadone 
treatment providers, a lack of provider knowledge 
surrounding methadone treatment, or some other reason.  
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Treatment Provider Survey
Medication-Assisted Treatment for Opioid Use Disorder
Buprenorphine
While treatment providers (including methadone clinics, n=19) more commonly 
reported either prescribing or referring  for buprenorphine more than any 
other pharmacotherapy, there was one provider in Hall county and two providers 
in Lancaster county that neither prescribe nor refer clients for buprenorphine.  
Despite more providers indicating they prescribe or refer buprenorphine more than any other 
pharmacotherapy, only inpatient and methadone providers in three counties indicated 









Douglas Hall Holt Lancaster Madison Sheridan
Neither Prescribe Refer
Naltrexone
All but two inpatient facilities indicated they either prescribe or refer for 
naltrexone, making it, together with buprenorphine, the medication more 
inpatient facilities prescribe or refer for than any other pharmacotherapy.  
Methadone clinics were excluded from this analysis as naltrexone seemed to be outside of the 
scope of their services (two methadone providers did not answer, and one indicated they neither 
prescribe nor refer for naltrexone).  Since naltrexone is indicated for the use of both opioid and 









Douglas Hall Holt Lancaster Madison Sheridan
Neither Prescribe Refer
Inpatient Facility Naltrexone Prescription and Referral by County (n=17)




Medication-Assisted Treatment for Opioid Use Disorder
MAT Availability for Opioid Use Disorder
Providers identified four counties that prescribe at least one MAT pharmacotherapy 
to treat OUD.  Because naltrexone can be used to treat OUD or Alcohol Use Disorder, 
it is unclear whether Madison county has a MAT prescriber for clients with OUD.  No 
providers indicated a MAT prescriber in western Nebraska for clients with OUD.
Lancaster County (n=8)
Since providers indicated that most beds in the state for OUD are in Lancaster 
county, evaluators noted a relationship between those inpatient providers with OUD 
beds in Lancaster county and their reports of prescribing or referring for MAT, 
particularly for those pharmacotherapies indicated for OUD.  Three inpatient facilities in 
Lancaster county indicated they reserve 65 beds for OUD (two facilities have 25 beds each; one 
facility reported 15 beds).  Of these three facilities, none of them indicated they refer or 
prescribe for methadone.  Two of these facilities indicated the ability to prescribe for 
buprenorphine and naltrexone.  The remaining facility indicated they neither refer nor 
prescribe for any pharmacotherapy medication listed on the survey, including those for 
psychiatric disorders.  
MAT Pharmacotherapies Prescribed by County for Clients with OUD
Providers identified Douglas and Lancaster as the only counties that prescribe all 















Most inpatient facilities 
indicated they either 
prescribe or refer for 
acamprosate.  Four inpatient 
facilities indicated they neither 
prescribe nor refer for 
acamprosate.  Interestingly, three 
of those facilities are located in the 
metropolitan areas of Lancaster 
and Douglas counties.  Methadone 
clinics were not included in this 
analysis as this pharmacotherapy 










Douglas Hall Holt Lancaster Madison Sheridan
Neither Prescribe Refer
Inpatient Facility Acamprosate Prescription and 
Referral by County (n=16)
Disulfiram
Fewer inpatient facilities 
prescribe or refer for 
disulfiram than any other 
pharmacotherapy (n=8, 50%), 
except methadone. Only three
facilities indicated they prescribe 
disulfiram, while five indicated they 
refer for the medication.  
Methadone clinics were excluded 
from this analysis as disulfiram 








Douglas Hall Holt Lancaster Madison Sheridan
Neither Prescribe Refer
Inpatient Facility Disulfiram Prescription and 
Referral by County (n=16)
Medication for Psychiatric
Disorders
All but two providers 
prescribe or refer for 
psychiatric 
medications (n=18).  Seven 
providers prescribe medications 
for psychiatric disorders and nine 
providers indicated they refer out 
for this medication.  Both 
methadone clinics and inpatient 
facilities were included in this 
analysis.  







Douglas Hall Holt Lancaster Madison Sheridan
Neither Prescribe Refer
Medication-Assisted Treatment for Alcohol Use Disorder





No transportation/too far away
No health care coverage and cannot afford cost
Takes too long to access treatment





Family members/others are unsupportive
Misconceptions or stigma surrounding treatment
Do not want others to find out they need treatment
Fear of having children removed from the home
Lack of Support
Few providers reported that people do not seek treatment due to reasons 
related to lack of support.  Within this category, providers most frequently 




Reasons to Not Seek Treatment
What are the most common reasons people do NOT receive treatment? (select all that apply)
The full list of response options are provided in Appendix B.
For this item, providers could list an unlimited number of reasons why their clients did not seek 
treatment.  Providers gave a collective total of 83 responses (n=17).  Of those 83 responses, 64% 
were categorized as “intrinsic reasons,” 22% were deemed “access to treatment” issues, and 











Some providers reported systemic barriers to clients seeking treatment.  The most 
common barriers involved availability of treatment beds. One methadone 
provider from Douglas County and two inpatient providers from rural counties reported clients 







Too stubborn/prideful to go
Do not know how to access treatment
Do not think treatment will help
Do not want treatment; lack motivation
Do not think they need treatment
Not ready to stop using
Intrinsic reasons
Most providers indicated clients do not seek
treatment due to intrinsic reasons.   Over half of 
providers reported clients do not seek treatment because 
they are not ready to stop using, do not think they need 
treatment, or do not want to seek treatment. 












Overdose, or witnessing an overdose
Injury or near-death experience
Other health issue





Which of these statements best describes how your clients were prompted to get treatment? 
(select all that apply)




Ordered to get treatment
8Someone else thought they should
Courts
Providers indicated their clients were prompted to 
get treatment due to court-related incidents more 
than any other catalyst (n=14).  Of the three providers who 
indicated “other,” one stated “legal issues; trying to look good 
before sentencing” and the other stated that “probation, 
employer” prompted their clients to seek treatment.
Other People
8 of the 17 providers stated their clients sought treatment because “someone else
thought they should.” Six of the providers who identified other people as the catalyst 
for their clients’ treatment also reported their clients were ordered to get treatment.
Intrinsic
Approximately one-fourth of providers (n=7) identified intrinsic reasons as a catalyst 
for their clients to seek treatment.  Of the intrinsic options, providers most often 
stated their clients “decided on their own to get treatment.”
For this item, providers could list an unlimited number of reasons why their clients do not seek
treatment.  Providers gave a collective 32 responses (n=17).  Of those 32 responses, 53% were 
categorized as “courts” (including other legal entities), 25% were related to “other people” 
supporting clients, and 22% were classified as “intrinsic.”





What training have you received that has been helpful to your work? 
1. Evidence-Based Practices
Providers most often indicated that training on evidence-based practices (EBPs) 
was helpful.  EBPs specifically mentioned were medication-assisted treatment 
(MAT), eye movement desensitization and reprocessing (EMDR), dialectic 
behavioral therapy (DBT), and motivational interviewing, among others.
1. Trauma-Informed Care 
Four respondents indicated trauma-related trainings such as trauma-informed 
care and adverse childhood experiences (ACEs) have been beneficial. 
1. Substance Trends
Four respondents reported training on substance use trends were useful to staff, 
including the one methadone provider who responded to this question. 
1. Crisis intervention 
Two respondents also indicated crisis intervention trainings were helpful.  
Providers specifically mentioned trainings on de-escalation, suicide prevention, 
and co-occurring disorders have been helpful.
“We do consistent monthly trainings with staff on new controlled substances and 
how the public are using them.”





Needs of Treatment Providers
What additional resources or training do you or other staff at your facility need? 
1. Funding
Three participants reported a need for funding to expand their workforce 
capacity.  More specifically, they noted a need for case managers to assist MAT 
prescribers, professional staff to provide mental health services, and additional 
support for rural treatment providers (n=4). 
1. Evidence-Based Practices
The providers who indicated a need for EBP training specifically mentioned MAT 
training and American Society of Addiction Medicine (ASAM) criteria training.
“Our program urgently needs funding to meet the mental health needs of our 
clients.  Access to mental health services is nonexistent.”
- Inpatient Provider
“ASAM Criteria needs to be taught to private and State funded providers in rural 
areas.”
- Inpatient Provider
“Our prescribers in our outpatient office are open to prescribing MAT , but they will 
not do it without supportive staff in place to help manage these clients… We 
currently do not have funding for this, so we have not been able to implement MAT 
with our prescribers in our outpatient facility.”
- Inpatient provider
“I do not believe DHHS knows anything 







Which of the below topics would be useful for future training for yourself or other staff at your 
facility? (select up to 5) 







Trauma-informed care Physical and mental
effects of substance
misuse
Providers most often indicated interest in receiving training on evidence-based practices 
(n=11).  Nearly half of providers replied that future training on medication-assisted treatment, 
trauma-informed care, and the effects of drug use would be useful. 
Future Training Topics
Providers most often indicated interest in receiving training on evidence-based 
practices (n=11). 
Needs of Clients
What additional resources do your clients need? (select up to 5)
The full list of response options are provided in Appendix B.
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Over half of providers (two of whom are methadone providers) identified financial assistance for 
MAT as the most common need for their clients.  Providers also identified childcare as a client 
need in this item and in the following open-ended item.  
Needs of Clients






What would you most like DHHS to know about your clients, and your work? 
1. Client Finances 
Of the 11 providers who responded, 4 providers shared client finances are a 
significant concern.  According to these providers, financial limitations lead to 
clients leaving treatment too early and resorting to illicit ways of making money.  
Financial concerns prevent clients from being able to afford MAT and from being 
able to afford the transportation to access treatment.
1. 2. Care of Children 
Two providers indicated concerns about childcare for parents who are seeking 
treatment.  One shared the desire to see fathers eligible for reunification with 
children at the same rate as mothers after receiving substance use treatment.  
Another provider conveyed the need for residential treatment facilities 
equipped to house both mothers and their dependent children in order to 
increase the accessibility of treatment for mothers.
1. 3. Mental Health 
Two providers identified a lack of accessible mental health services.  One of 
these providers shared that mental health providers are particularly hard to 
access in rural areas.
“In the panhandle we do not have the resources to help all clients.”
- Inpatient Provider
“We have so many patients who discontinue treatment early due to a lack of funds.  
Most go back onto the street for drugs as they can get drugs by selling other drugs 
and using their bodies.”
- Methadone Provider 
“One of the primary factors preventing mothers from getting treatment is lack of 
long-term childcare and an unwillingness to leave their children... DHHS must 
prioritize residential treatment for mothers with their children to break the cycle 
of addiction in families.”
-Inpatient Provider
Three primary themes were identified from the responses of providers:
1. Client Finances,
2. Care of Children, and
3. Mental Health.
Providers included other concerns such as the importance of harm reduction interventions, the 





Most Helpful Prevention Efforts
In your opinion, what prevention efforts are most helpful? (Select up to 3 in each category)
The full list of response options are provided in Appendix B.
Medically based prevention
• Prescriber education.
• Addiction screening at primary care 
facilities. 
• Use of Prescription Drug Management 
Program (PDMP) before prescribing 
controlled substances.
• Addiction screening for those presenting 
for early refills. 
Prevention Efforts included in Categories








Education Social Service MAT
Helpfulness of Prevention Efforts by Category (n=17)
Providers reported that 
“medically based 
prevention” efforts, 
specifically prescriber education, are 
the most helpful, followed by 
“education,” “social service efforts,” and 
“MAT.”  Providers indicated that school-
based prevention education for middle 
school students was the most helpful 
education intervention.  Providers rated 
mental health services and counseling 
as the most helpful interventions within 
the “social service” category.
Social Service
• Increased access to mental health 
treatment.
• Mandatory counseling and services with 
buprenorphine or naltrexone 
administration.
• Increased access to 12-step programs.
• Increased access to and training on 
naloxone.
• Education about safe injection practices.
Education
• School-based substance misuse prevention 
programs—middle school students.
• School-based substance misuse prevention 
programs—elementary students.
• PSA and media campaigns for general 
public.
• Public education about MAT.









Populations in Need of Prevention Efforts
In your opinion, what populations are most in need of additional substance abuse prevention 
efforts? (select up to 5)
The full list of response options are provided in Appendix B.
Providers reported youth ages 12 to 17 years are most in need of prevention efforts, 
followed by adults and young adults.  Out of all the categories not based on age 
group, providers considered “individuals with mental illness” to be the most in need.  
Few providers indicated older adults age 65 years and over, persons in urban areas, and specific 








Populations Most in Need of Prevention Efforts 
Providers indicated youth ages 12 to 17 years are most in need of prevention 
efforts (n=17).
Populations in Need Responses
Youth (ages 12-17) 13
Adults (ages 26-64) 10
Young adults (ages 18-25) 8
Individuals with mental illness 8
Families living in poverty 7
Incarcerated individuals 7
Persons who lack a stable residence 7
Persons in rural areas 6
American Indians/Alaska Natives 5
Current substance users 4
Children (ages 5-11) 3
Populations in Need Responses




Older adults (ages 65+) 2
Persons in urban areas 2
Latinos/Latinas 2








While most providers indicated at least some knowledge of funding for 
buprenorphine, approximately one third of providers neither had knowledge nor 
ever referred clients to this resource.  Almost half of providers reported they are 
unsure about the helpfulness of this resource or that the resource is not helpful.  One inpatient 
provider from Lancaster county indicated their program is well informed about funding for 
buprenorphine, regularly refers clients to this resource, and the resource is very helpful.
None, 31% Some, 31% Well informed, 38%
Never, 38% Occasionally, 56% Regularly6%
Unsure/Not 







Following is a list and description of prevention efforts DHHS is currently involved 
with.  Please rate your degree of knowledge about the program, and the degree to 
which you find the program helpful.  We would also like to know the degree to which 
you have utilized the information and resources provided by these programs and initiatives for 
yourself or for your clients.
Client Referral
• We never refer clients to this resource 
• We occasionally refer clients to this resource 
• We refer clients to this resource regularly 
• We sometimes refer clients to this resource 
Response Options:
Knowledge
• I have no knowledge of this initiative
• I have heard of the initiative, but don’t know much about it
• I have some knowledge of the initiative and its activities











Nearly all providers reported no knowledge or utilization of the OpiRescue Phone 
application.  Of the 13 providers who rated the helpfulness of the OpiRescue Phone 
application, 11 reported uncertainty about the helpfulness of the resource.  One 
inpatient provider from Douglas county indicated the phone application is “very helpful” (n=13).
None, 82% Some, 18%
Never, 93% Sometimes, 7%
Unsure/Not 







Following is a list and description of prevention efforts DHHS is currently involved 
with.  Please rate your degree of knowledge about the program, and the degree to 
which you find the program helpful.  We would also like to know the degree to which 
you have utilized the information and resources provided by these programs and initiatives for 
yourself or for your clients. 
Utilization
• We never use this resource 
• We sometimes utilize this resource 
• We occasionally use this resource 
• We utilize this resource regularly 
Response Options 
Knowledge
• I have no knowledge of this initiative
• I have heard of the initiative, but don’t know much about it
• I have some knowledge of the initiative and its activities










Increase Medication-Assisted Treatment (MAT) Workforce Capacity
Most providers indicated at least some knowledge of this MAT resource.  Though less 
than half of providers replied they utilized it, more providers specified using this 
resource than any other on the survey, except for referring clients to funding for buprenorphine 
(n=17).  Over half of providers, however, reported being unsure of its helpfulness (n=14).  
None, 29% Some, 59% Well informed
12%
Never, 53% Occasionally, 47%







Following is a list and description of prevention efforts DHHS is currently involved 
with.  Please rate your degree of knowledge about the program, and the degree to 
which you find the program helpful.  We would also like to know the degree to which 
you have utilized the information and resources provided by these programs and initiatives for 
yourself or for your clients. 
Utilization
• We never use this resource 
• We sometimes utilize this resource 
• We occasionally use this resource 
• We utilize this resource regularly 
Response Options 
Knowledge
• I have no knowledge of this initiative
• I have heard of the initiative, but don’t know much about it
• I have some knowledge of the initiative and its activities











Despite indications that providers had more knowledge about naloxone 
distribution than any other resource on the survey, only about one third of 
them reported occasionally or regularly utilizing this resource.  One Douglas 
county inpatient provider reported regularly using naloxone distribution and indicated it as 
very helpful in their program.  Half of providers found naloxone distribution to be at least 
somewhat helpful, while the other half reported they were unsure of its helpfulness.  One 
provider reported naloxone distribution as not helpful.  
None, 18% Some, 47% Well informed, 35%











Following is a list and description of prevention efforts DHHS is currently involved 
with.  Please rate your degree of knowledge about the program, and the degree to 
which you find the program helpful.  We would also like to know the degree to which 
you have utilized the information and resources provided by these programs and initiatives for 
yourself or for your clients. 
Utilization
• We never use this resource 
• We sometimes utilize this resource 
• We occasionally use this resource 
• We utilize this resource regularly 
Response Options 
Knowledge
• I have no knowledge of this initiative
• I have heard of the initiative, but don’t know much about it
• I have some knowledge of the initiative and its activities










STEPs emailed the anonymous survey link to one administrative contact, provided by 
DHHS, per treatment facility or clinic.  The email may have inadvertently been sent to 
a spam folder or recipients may not have recognized the sender and ignored the email, so STEPs 
used follow-up emails and phone calls to increase the survey response rate.  Some providers 
were never reached which negatively impacted the response rate.
2. Incomplete Survey Responses
24 providers started the survey, but only 20 respondents completed both the 
demographic questions and at least one other item.  Several others did not complete 
many of the survey items (as noted by total n in each survey item throughout the report). 
3. Disproportionate Representation from Urban Counties
Relatively few treatment facilities outside of Douglas and Lancaster counties replied.  
Even fewer responses were received from the western two thirds of Nebraska, and 
thus we know very little about rural substance misuse behaviors, especially how those in central 
and western Nebraska might differ from the eastern third of the state.
4. Limited Scope of Services Sampled
This report covers only inpatient facilities and methadone clinics in Nebraska.  The 
perspectives of other treatment providers may differ substantially from our available 
sample.  Particularly for MAT, it is plausible that these services may be provided in facilities 
outside of the scope of this survey’s sample. 
5. Inpatient Versus Methadone Providers
Due to a difference in sample size, comparing 17 inpatient providers to 3 methadone 
providers may be misleading.  There are only 4 methadone clinics in Nebraska, so for 
many of the questions the survey results represent 75% of methadone providers.
6. Provider Self-Report
The measurement instrument asked providers to reflect on their perceptions of their 
clients’ experiences and behaviors.  This is may be less valid than asking individual 
clients about their own experiences.  
7. Aggregate Data
This survey asked providers to estimate the percentage of clients they see engaging in 
various drug use and treatment behaviors in aggregate form.  This does not reflect an 
actual count of providers referring clients for MAT or clients engaging in a specific drug use 
behavior.  From this survey, it is unknown at which rate clients actually engage in particular 
behaviors or access services such as MAT and prevention efforts.  Similarly, when providers 




1. Target prevention efforts to meet unique audiences.  
a. Aim the prevention of alcohol, marijuana, and methamphetamine at youth, and 
incorporate parents and peers into these efforts.
b. Aim the prevention of opioids misuse at prescribers and the medical community, along 
with clients and family members of those being treated for chronic or acute pain with 
narcotics.  
2. Revisit current methods of communicating with treatment providers about prevention 
efforts.  Assess how these efforts relate to the realized needs of treatment providers and 
their clients. 
3. Provide education to increase knowledge about MAT and to reduce stigma.  Education 
should be aimed at prescribers, substance abuse treatment providers, clients and their 
families, and the general public.
4. Assist treatment providers with training on evidence-based practices, especially those 
related to the treatment of trauma and MAT.  
5. Provide or coordinate funding for:
a. Treatment providers to increase workforce capacity, especially related to MAT, mental 
health care, and rural access.
b. Clients to pay for treatment, transportation to access treatment, and childcare to facilitate 
their participation in treatment.  
Treatment Provider Focus Groups
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Treatment Provider Focus Groups
Key Findings
Mental health professionals in medication-assisted treatment (MAT) facilities in Nebraska 
shared their experiences in providing treatment to individuals seeking treatment for substance 
abuse during three focus groups.  They were also invited to express their current needs as well 
as the needs of their clients. 
Drug Initiation
According to focus group participants, their clients with OUD are typically first introduced to 
opioids by friends or family or through doctors’ prescriptions.  Most of their patients are also 
struggling with trauma, like sexual violence, which makes them particularly vulnerable toward 
opioid misuse.
Education
Participants called for education on MAT targeting three distinct groups: professionals, clients 
and their families, and the general public.  
Professionals:
• Education for medical professionals should focus on how methadone works.   Many medical 
professionals seem to be engaging in an array of unethical prescribing practices, 
assumingly due to lack of knowledge.
• Some mental health professionals seem to need increased knowledge of MAT as a 
treatment option.
• Education for criminal justice professionals should focus on the range of substance use 
treatment options, especially those other than 12-stop programs and the use of MAT as a 
viable component of treatment. .  According to participants, the criminal justice system 
does not seem intentional or invested in patients’ recovery.
Clients and Their Families:
• Patients and their families could benefit from an increased understanding surrounding the 
length of treatment, and the role of medication as part of a holistic approach to treatment. 
General Public:
• The public seems to have many misconceptions surrounding substance misuse.  From the 
perspective of MAT providers, the public lacks knowledge surrounding the presence of 
opioid misuse in their communities and about addiction, treatment,  and recovery.  
Ethical Prescribing
Focus group participants also described prescribing practices that have harmed their clients.  
They spoke of medical doctors pursuing MAT when they are not licensed to do so.  While some 
medical professionals are over-prescribing pain medications, others are abruptly discontinuing 
long-term pain medications—both harmful practices, according to MAT providers.  
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Treatment Provider Focus Groups
Key Findings (cont’d)
Stigma
Treatment providers identified stigma regarding substance use disorders and MAT options as 
barriers to their clients’ recovery.  Too often, clients are viewed negatively by professionals and 
the general public due to their addiction struggles which is hard for providers to see when they 
work so hard to empower their clients.  
Financial Barriers
Many clients experience significant barriers to entering into treatment including the cost of 
treatment and the distance they must travel.   
Treatment Silos
Finally, focus group participants lamented the disconnect between educational requirements 
and treatment options for mental/behavioral health and substance use disorder.  This results, 
they shared, in treatment silos which are detrimental to client recovery. 
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Treatment Provider Focus Groups
Methodology
STEPs conducted three focus groups with treatment providers at medication-assisted treatment 
(MAT) facilities in Nebraska.  The purpose of these focus groups was to explore the experiences 
of mental health professionals and to understand more about the supports they and their 
clients need.  The intention was also to build relationships with professionals in the treatment 
community. 
The focus groups followed an intentional format of questioning to gain insight into opioid 
treatment and substance misuse trends.  Due to time constraints for the participants, the focus 
groups lasted an average of 90 minutes.  (See consent and script in Appendix D.)
Sample Description
STEPs collected limited demographic information to respect confidentiality and encourage 
candid discussion.  Most focus group participants indicated they were counselors or mental 
health practitioners with an average of 6 years’ experience.







STEPs utilized thematic analysis (Riessman, 2008) with in vivo coding (Saldana, 2016) to gain 
insight into participants’ experiences, with a focus on story and lived experience. The emphasis 
in this form of coding is the participants’ word choices.  Since focus group participants 
represented a microculture of mental health providers, this form of coding highlighted their 
voices and stories and relied on them to give the data meaning (Saldana, 2016).  STEPs’ coders 
included one graduate student staff and one Ph.D. project lead.  Coders co-facilitated two focus 
groups, and the project lead completed one focus group.
STEPs coded all interviews separately and then the two coders met together to reach consensus 
on emerging themes for each focus group.  Coders then compared across focus groups to derive 
overall themes from the transcripts.  In this study, reflexivity is critical to provide 
trustworthiness to findings (Morrow, 2005).  In coding separately and then comparing themes 
in this manner, STEPs was able to practice reflexivity and strengthen findings.  Participant 
quotes played an integral role in deriving and presenting themes through their voice.
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Treatment Provider Focus Groups
Results
At the close of qualitative data analysis, several themes emerged concerning the barriers to 
recovery experienced by individuals seeking treatment for substance misuse and substance use 





4. Financial Barriers; and
5. Treatment Silos.  
Themes and subthemes discovered during analysis are shown in the figure and detailed below 





























Focus Group Themes and Subthemes
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Treatment Provider Focus Groups
Education
Participants identified a need for education with three subthemes: 
Education for Clients and Their Families;
Education for the General Public; and
Education for Professionals.
Education for Clients and Their Families
STEPs asked participants what services their facilities provided.  One common response was to 
provide information about recovery to clients and their families.  Participants noted that many 
clients and their families believed that recovery could be achieved quickly.  Many held their own 
beliefs and biases on the use of medication in recovery.  The importance of a holistic approach 
to recovery, including psychoeducation for both the clients and their families, emerged in the 
focus groups.
“The reason why the education piece is so critical here is because there is a lot of stigma.  
So, a lot of times, you'll have pushback from family members: ‘Oh, you're on that 
methadone.’  And so for us, to kind of help create a healthy environment for our patients, a 
lot of times it is bringing in their significant other, or their parent, or even sometimes their 
children to help them understand the process, and what the program is really about.”
Participants shared that they often provide education to all involved in the client’s life.  Through 
their holistic approach, they said they provide education on both physical and mental 
components. 
“We utilize methadone to help with people who are struggling with opioid addiction.  If 
they do counseling, those who are qualified get approval for, like, couples counseling, if 
needed.  We provide patient education.  We provide education to the public, too, and the 
spouses, significant others, family members.  We provide education, we provide drug 
screens, we provide blood work, physicals.”
“I've done sessions with the patient's mom and the partner, and they said, ‘Oh, we're here to 
understand what methadone is, how it affects them, how the aspects of treatment work.’  
It's not a quick fix.  You can't come and dose for a week and be done.”
Education for the General Public
STEPs asked participants to discuss their view on the education level regarding medication-
assisted recovery (MAR).  Focus group participants expressed a general lack of understanding 
of what is involved in MAR.  Participants also noted a connection between the general public’s 
misconceptions of individuals who struggle with opioid addiction and the media’s portrayal of 
them.  These misconceptions lead to their clients’ dehumanization and allow the general public 
to stay removed from the issue.  Despite increasing media campaigns on opioid misuse in recent 
years, many Nebraskans hold onto the belief that it is not happening in our state.   
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Treatment Provider Focus Groups
Education (cont’d)
“It's amazing what you see, like heroin... the people that are dependent on heroin that come 
in here, because you don't really honestly realize that there is heroin out there.  Yeah, 
there's quite a bit.  There's a lot, and it's just, because we hide it so well here in Nebraska 
'cause we're such a conservative state, it's kind of, I don't know... it's humbling when you 
come into a practice like this, and you see people off the streets and what they're struggling 
with and it's like, wow, I had no idea this was a serious issue up here.”
STEPs found that there is a misunderstanding of how methadone treatment works.  The 
providers spend a lot of time educating and reeducating on how the treatment process works.
“It's not harmful to be on (methadone) for an extended period of time, so we would rather 
have someone be on this and be successful than feel pressured to have to get off of it… and 
then continue to fail.”
“Two to five years is how long it takes the brain to heal, so we recommend them to stay at 
the therapeutic dose, once they get to it, for at least 18 months before they start to 
decrease, because that gives them time to learn the coping skills.  It gives their brain a 
chance to heal, and creates further stability in their lives, before they start adding another 
stressor of decreasing the methadone, and eventually getting off.”
The providers’ ability to fulfill multiple roles is also vital to the success of the client. 
“We are also kind of the go-between for the patients.  Part of our role is the case 
management aspect of the patient… so we process through a lot of what that means to the 
patient, how they're doing on their (methadone) dose.  If they're needing any kind of 
adjustments, then we pass the word on to the doctor, and he makes the adjustments as need 
be.”
Providers expressed frustration with past prevention efforts and how the “Just Say No” 
approach is still a trend.  A common theme was that providers’ clients will use substances 
illicitly to cope with the trauma they have experienced.  Prevention is not as easy as “just saying 
no”–providers were adamant about mental health being a factor. 
“All of us know that mental health and addiction go hand in hand, and, like, the whole 
DARE program when we were younger… It never talked about anything except what a drug 
is, and how it works on your body, and why not to do it… saying, ‘Just say no,’ doesn't really 
work if you have anxiety and depression, and you're trying to get rid of all of those other 
things.  Going back to the mental health aspect, is huge.  I think that's one of the ways to 
help, 'cause if you have a healthy person, a healthy person's not gonna want to escape with 
drugs.”
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Treatment Provider Focus Groups
Education (cont’d)
Education for Professionals
Participants struggled with the lack of education and awareness surrounding MAR in the 
medical community.  They related how clients experienced doctors and nurses calling them 
“junkies” for using methadone in recovery, among other instances of verbal abuse.  Participants 
were particularly passionate about the lack of understanding of MAR in the mental health 
community.  Clinicians in Nebraska may not know that such treatment options exist in the state, 
and therefore cannot refer their clients to a potentially helpful treatment.  
Medical professionals lack an understanding of how methadone works, often jeopardizing 
recovery by refusing to give needed medication to those seeking treatment at a hospital. 
“(Clinic) patients go to the ER for…  I had one, had been injured at work, and he went to the 
ER, and they're like, ‘Well, you're on methadone, you don't need any painkillers.’”
"(Clinic patients) are like, 'Well, I went to the ER, but I won't say I'm on methadone because 
the methadone isn't covering my pain.  It's keeping me from misusing opiates, but then I 
won't get opiates if I tell them I'm on methadone." 
“When we're talking to parole officers, when we're dealing with courts, when we're dealing 
with (a treatment center), trying to get people in to get off of other things, they are so 
uneducated when it comes to methadone and even suboxone or buprenorphine.  Anything 
that we use to help people get off of opioids.”
Additionally, many mental health professionals do not realize that MAT is a treatment option 
in Nebraska.  Providers related how often Alcoholics Anonymous (AA) is considered the sole 
option for treatment.
“(Alcoholics Anonymous, AA) was less effective.  (AA’s) 5-10% success rate in a year's time 
was equal to zero treatment at all, AA by itself.  And so, I think we're… Times are changing 
but we're not going to remove (AA) from culture because it's been there for so long… I'm 
not against it, but it's not treatment, and it's not going to be a one size fits all.  It's not 
going to work for everyone.”
The providers gave many examples of how their interactions with suggested criminal justice 
departments had a frustrating lack of focus on recovery.
"Sometimes probation officers mandate that people go to 12-step programs.  And that's 
great for some people, but that's not… that doesn't work for everybody." 
"But it's not treatment, you know, 12-step recovery is not.  Unless it's facilitation in 
addition to therapy."
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Education (cont’d)
Often, it seems the system sets up clients to fail when it orders those seeking treatment to 
complete tasks they do not have the resources for.
“(Patients are) court ordered to go to treatment and sometimes they can't afford it to begin 
with.  Sometimes the state helps.  But then there's also the piece of the state–if you can't 
afford it, they don't pay for medication.  They don't pay for mental health appointments or 
medication.  And so you're left with some gaps, especially if you're working with someone 
who has been used to this dopamine overload in their brain or whatever else, from the 
meth or whatever else drug they've been using, and now you're just pulling them off of it.”
The providers struggled with how the criminal justice system did not seem intentional or 
invested in clients’ recovery.
"(Patients) don't need to be held captive.  They need long-term recovery."
"When people go to jail, whether on work release or whatever else, there is… It depends on 
the medication, sometimes there is just a lapse… There are other medications they just flat 
won't allow inmates to take.  And sometimes that's the very thing that's helped them stay 
clean and sober, and to be able to survive or do well… It makes me question what the 
expectation really is.  To make them pay?  Well how… What are we doing to them and to 
our culture and our society, our community in the long run, by just yanking them off of
those things, and expecting them to just tough it out?  I think that's insane.”
“I just got into an argument with (staff at jail) for like…  ‘This person can bring in their 
benzos (to jail), but they can't bring in their methadone.’  ‘Well explain to me why they can 
have their benzos but not their methadone?’  ‘Well we just don't do that there.’  ‘Okay, well 
this person's gonna have their dose.  If you medically feel that you can trump my doctor, 
please write me a letter stating that you're gonna take care of 'em and you think this is the 
best for him and whatever outcome.’  So finally, they're like, ‘Just have them bring it’ and 
they got it.”
Ethical Prescribing
Participants indicated clients have issues with prescribing practices at their treatment facilities.  
These issues included: 
Unauthorized Prescribing of Medications for Opioid Use Treatment; 
Over-Prescribing Pain Medication; and 
Abruptly Discontinuing Long-Term Opioid Prescriptions without providing 
treatment or referrals.
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Ethical Prescribing (cont’d)
Unauthorized Prescribing of Medications for Opioid Use Treatment
According to participants, medical doctors are pursuing MAT when they are not licensed to do 
so.  This problematically continues the stigma and legitimate MAT clinics are dealing with the 
aftermath.
“(Patients) need to be in a medication-assisted treatment facility.  Now, methadone is 
prescribed for pain, but when you're treating opioid addiction, it needs to be in a setting 
like this.”
“There are physicians that are prescribing methadone for patients when they're not 
supposed to.  You have to be a buprenorphine provider to prescribe methadone for anyone.  
So, we've… a couple times ran into doctors that are writing methadone scripts anyhow and 
then, I mean, then you have the DEA go in and they're closing down the clinics.”
Over-Prescribing Pain Medication
Unethical prescribing was a recurring concern in the focus groups, and several providers shared 
how these practices have harmed clients.  According to participants, doctors are part of the 
reason people are struggling with addiction to opioids.   
“That's the commonality… The doctors prescribing all thism and then before they know it, 
these guys can't stop.  ‘I couldn't stop on my own,’ ‘I ran out before I was supposed to.’  
That's a big commonality.”
“I had one client who ended up actually OD-ing.  She had been put on opioids at age 11 for 
some problems with cramps and just terrible pain.  And so the doctor put her on opioids for 
that and they refused, no matter how much she begged throughout her years, to have a 
hysterectomy… they said, ‘You're too young, we won't don't that.’  But they did some other 
things for her.  But then she escalated into stealing a prescription pad.”
“I had a client come in the other day…  And she had done karate and broke her toe, her little 
toe.  Went to the emergency room and because she was urged to do so, not because she 
necessarily felt that she was in so much pain, so they did what they needed to do, double 
wrapped her toe to the next one, blah blah blah.  And then (the physician) writes her a 
prescription for 10 Hydrocodone or something like that.  And she said, 'I don't need these.'  
He said, 'Well just don't fill it then.'  But he gave her the prescription.  It's crazy.  It's BS.”
“But I would say, the ones who've strictly used the opiates are the ones that got addicted to 
it because of the doctor.  Some didn't even start their addiction ‘til they're in their 30s.”
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Ethical Prescribing (cont’d)
Providers are now seeing how it has become common practice for doctors to prescribe anxiety 
medication without a thorough assessment of awareness of the danger, leading to a trend in this 
type of opioid addiction. 
“I'd say another big trend that I've noticed within the last year is benzos, benzos and 
opioids combined, we are seeing a ridiculous amount of people who are getting prescribed 
benzos.”
“Of the 300 (patients), I think 140 of them had benzos in them (drug screens).  And out of 
the 140, only 10 of them were illicit.  And that was a huge jump from the prior year, and so 
I may…  I know our patients are getting benzo scripts, or at least coming in with benzo 
scripts more often than previously.”
“(Clinic patients can) easily say, 'These are the symptoms I'm having,' and, 'It's not being 
controlled by non-medical means,' or whatever, and most doctors are kind of like, 'Okay, 
whatever, here's a benzo script,' not knowing that they're also taking methadone, or street 
drugs."
Abruptly Discontinuing Long-Term Opioid Prescriptions
According to many providers, doctors are abruptly stopping long-term prescriptions which 
leaves clients to deal with withdrawal and recovery without proper support.  Providers 
consider this sudden discontinuation of medication unethical.  In the mental health field, 
providers have to follow certain procedures to properly discharge a client from therapy, and 
participants wondered why doctors are not held to the same standard.
“Well, I think it's great that they're having doctors cut people off from their opiates, but 
they're not providing them with treatment.”
"I have a patient that was prescribed two different opiates for 12 years and then one day 
they (the prescribing doctor) just decided they were done.  You were cut off, you were 
kicked out, no more, and ended up here."
“I'd say a lot of it was when restrictions came too.  The doctors started cutting people off.  
They were first going out onto the streets before coming into treatment.”
“Or (new patients will) come in 'cause every so often the state patrol monitors, and so if 
they eventually go into a practice and say, ‘Well, okay, you've been prescribing this 
medication for this individual for X amount of years and why,’ so they may get scared and 
then it's like ‘Uh oh, no more.  This is your last script.’  So, they're just left hanging.”
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Ethical Prescribing (cont’d)
“And the doctors do make them feel like second rate, like they're a loser, and they may have 
legitimately had a health issue, chronic, you know, they talk about back pain has a huge, 
huge effect on people, and you can't get away, it's very hard to treat it.  And so, they're 
chronically dealing with this pain.  Well, if you have somebody who's chronically in pain, all 
they want to do is escape that.  And so, then they get in this cycle, where it's over and over, 
and how are they… Where are they supposed to go now that they don't have any pain 
medicine?”
Stigma 
Treatment providers identified stigma as a barrier to recovery, specifically related to:
Substance Use Disorders; and 
MAT Options.
Substance Use Disorders
Patients are often viewed negatively due to their addiction struggles.  This is frustrating for 
providers, who view people as more than their addiction.  The providers see the side of clients 
that is often covered by the stigmas of addiction.
“I would say, again, people are not bad, their behaviors can be unhealthy.  So keep in mind 
that that's a person–no matter what they're struggling with, whether it's opiate addiction, 
meth, whatever it may be… and not dehumanizing it.”
“They are a person.  They have a mother, they have a father, they have a life to live, too, that 
could be a healthy, fun, active life.”
Participants from one MAT facility spoke very passionately spoke of the level of commitment 
they have to their clients and how they work to empower them.
“We just show that we care and they're human beings and if they need something, we're 
gonna help them.  We'll go above and beyond if need be and it just shows that it gives them 
value as a human being.  Other places that they've dealt with treat them (that) way, that 
they're beneath their feet.  And to get treatment from somebody that gets to their level and 
respects them on that level as a human being, you tend to see them really fight for it and 
push for it.  If you fight for them, then they learn to fight for themselves.”
Their wishes included finding ways for DHHS to address stigma.
"I think they (DHHS) should lessen the stigma 'cause everybody has that judgment factor 
that they don't know much about addiction so with that stigma comes along.”
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Stigma (cont’d)
Another area of concern was the lack of resources for individuals trying to seek treatment or to 
detox in a safe way.  Often there is a lack of space for clients, and the MAT providers are left to 
pick up the pieces of an overdose, or see their clients with no place to detox use again.
"(A local detox center) will not take anyone detoxing off of opiates.  They are our biggest 
detox center, and they will not take anyone for detoxing from heroin, methadone, or 
anything."
“(Referring clients to treatment) is a little more difficult just because with methadone… not 
all the treatment facilities wanna deal with people on methadone."
MAT Options
The providers indicated inconsistencies and stigma within their own practices.  They also 
acknowledged stigma in the mental health community regarding what they actually do for 
clients.
“We're a methadone clinic, but there's this branding of Suboxone, and there can be 
misunderstandings about what each one of them can do, how each one of them work… I 
sure hear an awful lot of Suboxone commercials.  I don't ever hear anything about 
methadone.  Then I get that, part of it is the stigma, and I think that that.  If we don't… if 
we close the door on one avenue that may, Suboxone may not work for somebody, and this 
may be the key, that if they didn't have that opportunity, or if they weren't aware of that 
opportunity, we just left somebody out there to dry.”
"There are still substance abuse therapists and staff I know that just say, 'Oh no, you're just 
cross-addicting.  You're just using a substance to cure a substance, and that's just not okay.'  
And I would, I would beg to differ.  Yeah, that's just, that's ridiculous.”
A particular area of concern for providers was the stigma against pregnant women utilizing 
MAT.  According to providers, these women are treated in an unethical way which has an impact 
on their mental health.
“(A pregnant client) went in and (nurses) found out that she was on methadone because of 
an addiction that she's trying to take care of that was produced by a doctor, okay.  She was 
treated like crap.  She was in tears.  She even came back and on her paperwork, it said, 
‘methadone dependent’ and it's like that's not what it is, honey, because they're 
miseducated." 
“They immediately, you know, they (nurses) have to treat the babies if they're having 
withdrawals, and so, then the nurses’ kind of, ‘Oh, you're just a junkie… They're not because 
she's in recovery, and that's what she should say, 'I'm not, I'm in recovery.'"
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Stigma (cont’d)
An experienced provider stated that they have seen a shift in how methadone is perceived in 
different settings.  Their observation was that methadone stigma has been increasing.
"(In) the late 60s, early 70s, the jails allowed you to bring methadone in.  You can take it 
down there.  They would come pick it up or they would bring the patient.  And then as time 
evolved, they got new personnel in, and they had a different view of what methadone was 
and it was all of a sudden… it's like nope, you can't do it anymore.
I mean… and they (jails) did it for years, they allowed them to do that with no problem.  
They got new personnel in with different views and ideas and stigma about methadone, 
and we even had one nurse say, 'Well we don't give alcohol to alcoholics.'"
Financial Barriers
Focus group participants expressed frustration with how policy changes regarding treatment 
funding have impeded recovery success for clients, and related significant financial barriers 




Providers repeatedly talked about treatment cost as a barrier, and changes in policy and 
funding is concerning for MAT providers.
"Again, back to the late 60s, 70s, and all that, when methadone first came to Nebraska, 
when the first methadone clinic was opened, the government gave grants and paid for the 
methadone because people could not afford it.  It had a big impact to stop people from, the 
crime rate went down, homelessness went down.  They (patients) got it free.  As the years 
evolved, all that was taken away.  They cut this, they cut that, and pretty soon it was not 
available anymore, but we still had all those people that were out there addicted and 
needed the help."
"You think about the person that is struggling with addiction or substance abuse.  If they 
have insurance, great.  But the majority of them, they can't afford insurance.  They are your 
average Joe.  Or their insurance doesn't cover that type of stuff.  So, the funding to help 
them get their life back together isn't fair and that's such a disservice, and it's just 
disgusting, sorry.  I keep on saying that, but it's disgusting.  It's gross.”
Providers were adamant that DHHS hear the stories of the people impacted by insufficient 
resources to help with drug addiction in our state.  They find it very disheartening for clients to 
be unable to utilize resources that would aid in their recovery.
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Financial Barriers (cont’d)
"And that's where I see a big lapse as far as helping people in their recovery progress.  
There's not enough options for people that don't have the coverage… not enough beds out 
there for inpatients.  You have people on waitlists for three months, and you have to 
literally be homeless, suicidal, IV user, in order to get a bed right away." 
"What's really frustrating about the Nebraska system and why I think it's so broke, is 
because we are cutting back on the mental health issues and that's the stuff that needs to 
be addressed.  I mean there's so many people that need help and that goes beyond just 
substance abuse.  That is just really frustrating on our behalf because we try so hard for 
these guys.  We try and it's just shut door after shut door after shut door.” 
“I've got a patient right now who's been trying to get into treatment for more than two 
months, and Saturday she overdosed." 
“A lot of people don't have the money for the fees and stuff, and Nebraska doesn't pay for 
treatment for adults for drug treatment.  There needs to be monies available to help these 
people when they do come in for treatment that can assist them with the fees, with the 
housing, medical stuff, and it's just not there.”
Methadone clinic costs are also a deterrent for recovery success.  Providers gave several 
examples of how they have seen this play out with their clients.
“One of the biggest things is, is it's patients being able to afford (methadone treatment) 
ongoing.  We have patients come in here, and they'll have enough to get the program 
started, and then, nothing.  They can't afford the cost of it.  And so we find with the 
insurance providers, that sometimes be a little bit difficult to work with, or to get 
reimbursement for that.  The money is probably one of the biggest deterrents, or 
complications for patients to be able to be successful in treatment.”
“(Clinic patients) can be on the program for two months.  They're doing really well, then 
they run out of money, and then they just stop coming.  And it's sad for us to see because 
they were doing so well, and the only reason they quit was because of money."
“We had an admit today who wanted to come last week, but she didn't have the money, and 
then she came today, but she doesn't have a job, so we have no idea how she's gonna
continue with the program.”
"Family members always volunteer to help, but most of them stop after a couple months 
because they're tired of forking over $400 a month (for methadone medication) for them to 
be well."
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Financial Barriers (cont’d)
Transportation
Clients’ ability, or lack thereof, to get to the clinic was another frequent theme.  The large 
amount of time and resources, including a car and gas money, are significant barriers to 
recovery.  The lack of MAT clinics in rural Nebraska requires clients to drive.
“(Methadone clients) are all over.  I have one that drives from South Dakota.”
Even if clients have Medicaid, coverage for a ride to treatment is not guaranteed.  Providers 
stated provisions for transportation depends on their worker.
“We have a few (clients) that have Medicaid, for example, and I guess we're not Medicaid-
billable, but they won't transfer them to any methadone clinic, so they get stuck without 
medication.  They can be transported to a grocery store, but they can't be transported to 
treatment."
Providers also related how applying for a federal exemption delays the treatment process, and 
often has the client waiting for a long time to get the medication they need.
“(Methadone clients come from) Kansas, Grand Island, Hastings.  And they make that trip 
daily, until we can get them a federal exemption.  In order to get a federal exemption, you 
have to have two, at least two drug screens in a row.  With the new ways, we write an 
order, or I write an order up on the computer in the federal website, and there's no 
identifying information, it's just their admit date, what they need the exemption for, what 
their UAs look like.  And then it's either denied or approved. Usually if it's a travel 
exemption, they'll approve it.  But in order for them to get those two clean UAs, it can take a 
while, especially if their dose isn't therapeutic, and they're still abusing street drugs, they 
can be taking that hour and a half journey every day for two months.”
Treatment Silos
When STEPs asked participants about training on substance abuse treatment, many shared 
about their degree program course requirements.  They spoke about a disconnect between 
mental/behavioral health and substance use disorder educational requirements for licensure 
or certification.  According to participants, this disconnect leads to treatment silos which are 
detrimental to client recovery.  Providers are seeking connections within the disciplines to 
reveal addiction’s root cause, and hope this clarity will lead to a more comprehensive treatment 
plan that is more collaborative in application.
“Everything's so siloed in our field.”
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Financial Barriers (cont’d)
“(In the providers degree program,) we had pharmacology, biological bases of behavior, 
but I don't think we had a specific chemical dependency course, which is a problem.  I think 
things are too separated.  ‘Well that's chemical dependency over here, and this is mental 
health over here.’  Well wait a minute, like, when do you see chemical dependency without 
trauma?  I don't see it without trauma.  I don't think I've ever seen it without trauma.”
Providers are treating the whole person, not just the addiction.  This is paramount to successful 
treatment.
“Our (methadone treatment facility’s) main focus is on the opioid addiction.  However, in 
order for patients to be successful, all aspects of life have to be taken into consideration.  
We focus on more than simply just the addiction itself.  We focus on the relationships that 
they have with others, or their finances, or their employment, or their mental health.”
“I think educating (the public) on what it means to have anxiety, and what it actually is, is 
huge, and various aspects, in regards to getting prescribed medications, coping skills, 
educating yourself and your family members.”
Additional Messages from Providers
While many of the providers’ perspectives have already been covered, several additional items 
worthy of reporting emerged.
Providers expressed enthusiasm in sharing stories with STEPs.  They also appreciated DHHS’s 
genuine interest in their work and are glad DHHS wants to hear their voices, yet remain 
apprehensive that it will have an impact. 
In narratives of how their clients first misused a substance, providers said their clients are 
either introduced to opioids by friends or family or through doctors’ prescriptions.  There was a 
connection in the data between the theme of mental health and interpersonal struggles to the 
stories of how clients first misused a substance.
“I would say at least 50% have started with prescriptions, taking prescriptions from the 
doctor, and getting hooked that way.”
Additionally, all the providers talked about trauma being a part of most their clients’ lived 
experiences.   One clinic specifically related that all their clients, both male and female, reported 
sexual assault as a part of their history.  This is important when looking at trends in the opioid 
crisis because providers thought the media have made the crisis out to be something different 
than it is.  In looking at prevention efforts, trauma must be a major part of the conversation.
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Additional Messages from Providers (cont’d)
One clinic gave this demographic report:  
“90% of our people are Caucasian.  The majority of the people in age are between the age 
of 35 and 44, and then our second highest one, at 23%, are the 25 to 34-year-olds.  And 
currently, we have 14 patients over the age of 60.  Most of them, we have 16% of our 
patients are disabled, and 69% of them are employed.”
Providers also wanted DHHS to limit the amount of resources and energy the department 
focuses on prevention instead of treatment.  Providers were very committed to their current 
clients and wanted them to have a say in how DHHS moves forward.  They did not believe it was 
too late for their clients to achieve successful recovery, and were weary of how many systems in 
Nebraska dehumanized individuals who struggle with addiction.
“They're not thinking or considering all the people already addicted to opiates, the ones 
that got cut off from their doctor, the ones that are out on the streets using heroin 'cause
they don't have the money to come here, they don't have the resources, or they don't know 
that we exist.”
The providers wanted the opportunity to share an accurate view of their treatment approach 
and how holistic it is, and encouraged DHHS to visit MAT clinics to speak directly with 
treatment providers.  As one provider said:
“It needs to be an all-encompassing scope because it is an all-encompassing problem.  Like, 
one thing isn't gonna fix it.
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Limitations
1. While qualitative research is conducive to small sample sizes, more focus groups might have 
revealed themes not yet discovered in this analysis.
2. Focus groups were conducted in treatment programs in two of the larger cities in Nebraska 
and do not necessarily represent most treatment providers in Nebraska. 
3. Focus groups were conducted only in medication-assisted treatment programs and do not 
represent the views of inpatient or other outpatient programs. 
4. Time constraints on the length of focus groups may have limited participants from offering a 
full exploration of the topics.  
5. STEPs was unable to conduct a focus group with one key treatment provider despite several 
efforts to schedule one.
6. The risk of bias is involved in all qualitative research.  STEPs utilized two coders to limit bias 
in the coding of the data. 
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Recommendations
In light of the qualitative analysis of focus group responses from treatment providers, STEPs 
makes the following recommendations:
1. Create a pathway for increased communication and coordination between DHHS and 
treatment providers, as well as between mental health providers and the continuum of 
substance abuse treatment providers, ensuring seamless and holistic treatment to 
individuals seeking recovery. 
2. Reduce stigma for individuals who have misused, or are misusing substances. 
a. Provide psychoeducation on MAT (MAR) to clients and their families, the general public, 
and professionals. Education for professionals is critical in healthcare, mental health, and 
criminal justice settings. 
b. Be diligent about using language that aids in reducing stigma (i.e. “Medication Assisted 
Recovery” rather than “Medication Assisted Treatment”), and communicate with 
treatment providers about this language.  
3. Increase access to treatment options, including MAT (MAR), inpatient and outpatient 
programs, detox, and trauma-informed mental health care.  Reduce financial barriers to 
these services, specifically related to healthcare coverage and transportation.  
4. Promote ethical prescribing practices among medical professionals, including unauthorized 
prescribing, over-prescribing, and abruptly discontinuing prescriptions for those who have 
been on long-term opioid pain medication. 
In addition, focus group participants invited DHHS to their programs to hear directly 
from them about their experiences in providing treatment and other care to individuals 
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Age at First Use of Primary Substance
2017 U.S. Admissions Nebraska Admissions
11 years old and younger 5% 9% (1,124)
12-14 years old 18% 23% (2,938)
15-17 years old 26% 34% (4,347)
18-20 years old 19% 18% (2,238)
21-24 years old 12% 9% (1,107)
25-29 years old 9% 5% (492)
30 years and older 11% 3% (555)
100% 101%
Admitting Facility U.S. Data Nebraska Data
Ambulatory 62% 47% (6,334)
Outpatient 48% 40% (5,416)
Intensive outpatient 13% 6% (825)
Detoxification 1% 1% (93)
Rehabilitation/residential 18% 15%
Short-term (<31 days) 9% 10% (1,278)
Long-term (31+days) 8% 5% (705)
Hospital (non-detox) 0.4% -
Detoxification (24-hour service) 20% 38% (5,150)












1 day 11% 27%
2-10 days 23% 19%
11-20 days 8% 5%
21-30 days 8% 7%
31-45 days 7% 10%
46-60 days 5% 6%
61-90 days 9% 7%
91-120 days 7% 5%
121-180 days 8% 6%
181-365 days 9% 6%
>365 days 5% 3%
100% 100%






Ambulatory, detoxification 12% 1%
Ambulatory, non-intensive outpatient 39% 44%
Ambulatory, intensive outpatient 13% 7%
Rehab/residential, long term (more than 30 days) 9% 6%
Rehab/residential, short term (30 days or fewer) 9% 12%
Detox, 24-hour, free standing residential 18% 30%
100% 100%
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What are the most common reasons people do NOT receive treatment? (select all that apply)
Response Options:
• No health care coverage and cannot afford cost
• No transportation/too far away
• Takes too long to access treatment
• There are no openings in the programs 
• Family members/others are unsupportive 
• Fear of having children removed from the home
• Misconceptions or stigma surrounding treatment
• Do not want others know they need treatment
• Do not know how to access treatment
• Do not want treatment; lack motivation 
• They are not ready to stop using
• They are too stubborn/prideful to go 
• They do not think they need treatment 
• They do not think treatment will help
• Hours inconvenient
• Too embarrassed, ashamed
• Stopped using, treatment not indicated
• Other problems to deal with 
• Conflict of interest
What additional resources do your clients need? (select up to 5)
Response options identified by at least three providers:
• Condom distribution
• Facilities that accommodate women with dependent children
• Funding for rural area
• Education about MAT
• Naloxone kits
• Information on how to access treatment
The full list of response options can be found in the Appendices (link to appendices).
TEDS
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Appendix B: Treatment Provider Survey
*Note: Brand name pharmaceuticals were used in the survey to increase recognition of 
pharmacotherapies by treatment providers.  This in no way reflects support or endorsement by 
DHHS or STEPs of any particular company, medication, or therapeutic intervention.
Thank you for taking part in this important survey to gauge drug-use behaviors, 
treatment needs, and prevention efforts through the lens of treatment providers across 
Nebraska. 
This survey is part of a statewide needs assessment by the Nebraska Department of 
Health and Human Services' (DHHS) Division of Public Health to focus prevention efforts, 
provide training and other resources to treatment centers, prepare for a more in-depth study in 
the near future, and inform the statewide crisis response plan.
This survey is administered by STEPs (Support and Training for the Evaluation of 
Programs) through the University of Nebraska at Omaha.  Aggregate responses to this survey 
will be used by DHHS to allocate grant funds, resources, and develop crisis response plans. 
We expect this survey to take 10-12 minutes to complete.  Responses will be analyzed 
collectively by STEPs and individuals will remain anonymous.  The STEPs team will then 
provide a final report with recommendations to DHHS using your invaluable feedback.
Program Information
We would like to know about your program and/or facility, and the services that your program 
offers.  
1. What is your role within your facility? 
We understand that you may be involved in more than one role at your organization.  If you are 







oOther (please specify): ___________
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2. Which of these best describes your program?  (Select only one)
oResidential short-term treatment (similar to ASAM Level III.5, clinically managed high-
intensity residential treatment, typically 30 days or less)
oResidential long-term treatment (similar to ASAM Levels III.3 and III.1, clinically managed 
medium- or low-intensity residential treatment, typically more than 30 days)
oOutpatient methadone/buprenorphine maintenance or naltrexone treatment
oOutpatient day treatment or partial hospitalization (similar to ASAM Level II.5, 20 or more 
hours per week)
o Intensive outpatient treatment (similar to ASAM Level II.1, 9 or more hours per week)
oRegular outpatient treatment (similar to ASAM Level I, outpatient treatment, non-
intensive)
For all of the remaining questions, please answer thinking about the specific program indicated 
above (even if your organization has multiple programs, or you work in multiple programs).
3. Which of the following pharmacotherapies does your program either prescribe on site, or 
refer out for a prescription? 
4. How many beds or spots do you have dedicated to individuals with opioid use disorder?







Our program does NOT 
prescribe or refer for this 
medication
Disulfiram (Antabuse®) □ □ □
Naltrexone □ □ □
Acamprosate (Campral®) □ □ □
Medications for psychiatric 
disorders □ □ □
Methadone □ □ □
Buprenorphine □ □ □
Other (please specify) □ □ □
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5. In which county is your program located? 
(Listing of all counties, can select multiple)
6. In which counties do your clients typically reside? 
(Listing of all counties, can select multiple)
For this section, we are interested in hearing your perceptions of substance use trends.  We are 
examining the most common and most recent trends in substance use among the clients you 
serve, as we recognize these may be different from national trends.
7. Thinking about clients served in your program over the past year, approximately what 
percentage of these clients have presented needing treatment for the misuse of:
Misuse refers to any use of the substance other than that which is intended.  The substance need 
not be their primary drug of choice.  
(Choose % for each on a slider)
oAlcohol 
oPrescription Pain Relievers (i.e. hydrocodone, oxycodone, Demerol®, Percocet®, 
Vicodin®, etc.)
oHeroin
oFentanyl (Duragesic®, Abstral®, Ionsys®, Subsys®)(including prescription or illicit)
oMethamphetamines
oBenzodiazepines (i.e. Valium®, Xanax®, etc.)
oAntidepressants (i.e. Wellbutrin®, etc.)
oMarijuana
oHallucinogens (i.e. LSD, PCP)
o Inhalants
oCocaine/Crack
oOther (please specify) _______________
8. Thinking about clients served in your program over the past year, approximately what 
percentage of these clients were considered IV drug users? 
(Choose % on a slider)
9. Thinking about clients served in your program over the past year, what have been their most 
common primary drugs of choice?  (Select all that apply)
oPrescription Pain Relievers   (i.e. hydrocodone, oxycodone, Demerol®, Percocet®, 
Vicodin®, etc.)
oHeroin
oFentanyl (Duragesic®, Abstral®, Ionsys®, Subsys®)
oMethamphetamines
oBenzodiazepines (i.e. Valium®, Xanax®, etc.)
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9. Thinking about clients served in your program over the past year, what have been their most 
common primary drugs of choice?  (Select all that apply)
oAntidepressants (i.e. Wellbutrin®, etc.)
oMarijuana
oAlcohol
oHallucinogens (i.e. LSD, PCP)
o Inhalants
oCocaine/Crack
oOther (please specify) ____________
10. What percentage of your clients have an opioid use disorder (prescription pain relievers, 
fentanyl, heroin)? 
(Choose % on a slider)
11. In the past year, what percentage of clients in your program were polysubstance 
dependent? 
Polysubstance dependence refers to a type of substance dependence disorder in which an 
individual uses at least three different classes of substances indiscriminately and does not have a 
favorite drug that qualifies for dependence on its own. (Encyclopedia of Mental Disorders, 2019).
(Choose % on a slider)
12. We would like to know about trends you are seeing in the use of multiple substances.  For 
each of the primary substances listed below, please indicate the drug or drugs that you 
commonly see paired with each substance.  
(open ended box after each option)
oAlcohol 
oPrescription Pain Relievers (i.e. hydrocodone, oxycodone, Demerol®, Percocet®, 
Vicodin®, etc.)
oHeroin
oFentanyl (Duragesic®, Abstral®, Ionsys®, Subsys®)
oMethamphetamines
oBenzodiazepines (i.e. Valium®, Xanax®, etc.)
oAntidepressants (i.e. Wellbutrin®, etc.)
oMarijuana
oHallucinogens (i.e. LSD, PCP)
o Inhalants
oCocaine/Crack




For this section, we would like to hear your perceptions about your clients’ experiences of 
initiation to drug use.  For the purposes of this survey, “drug-use initiation” is defined as the 
first misuse of a substance.  For example, the first time binge drinking, rather than the first time 
tasting alcohol.  
13. What is your perception of the most common substance that is first misused by your 
clients?  For example, choosing alcohol would convey that most clients first began their misuse 









oOther (please specify) _____________
14. What age do most clients served in your program report as their first misuse?
o14 years or younger
o15-18 years old
o19 years or older
15. In your opinion, what are the most common reasons for clients’ first substance misuse?  
(Check all that apply)
oPain relief
oRelax or relieve tension 
oExperiment/see what it’s like 
oFeel good/get high 
oHelp with sleep 
oHelp be alert or stay awake
oHelp study
oHelp concentrate
oHelp with feelings or emotions 
oHelp lose weight
oParents or other family members encouraged them to
oPeers encouraged them to
oUnknown
oSome other reason (please provide reason) _________________
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Treatment Barriers and Facilitators
For this section, we would like to hear your perceptions about your clients’ treatment 
experiences.  We are interested to hear about what motivates clients to enter treatment 
(facilitators) and what prevents them from seeking treatment (barriers).  
16. Where did clients most commonly get the substance they first misused?
oGot from a doctor
oStole from Dr office, clinic, hospital, or pharmacy 
oGot from friend or relative for free 
oBought from friend or relative 
oTook from friend or relative without asking 
oBought from drug dealer or other stranger 
oGot some other way (please provide source) ____________
17. What are the most common reasons people do NOT receive treatment?
oNo health care coverage and cannot afford cost
oNo transportation/too far away
oHours inconvenient 
oThey are not ready to stop using
oThere are no openings in the programs 
oThey do not think they need treatment 
oThey do not think treatment will help
oThey do not want others to find out they need treatment
oToo embarrassed, ashamed, afraid/do not want to ask 
oDo not want treatment; lack motivation 
oStopped using, treatment not indicated 
oOther problems to deal with (emotional, family, etc.)
oThey are too stubborn/prideful to go 
oFamily members/others are unsupportive 
oConflict of interest 
oDo not know how to access treatment; do not know where to start
oTakes too long to access treatment; window of motivation closes before program has an 
opening
oMisconceptions or stigma surrounding treatment
oFear of having children removed from the home




A FREE phone application designed to walk individuals through what to do in the event that
they witness an overdose, provide resources to anyone on treatment, recovery, and where to get 
naloxone.  Information at:  https://opirescue.com/ Download through the Google Play Store or 
the Apple App Store.
I have no knowledge of 
this initiative
I have heard of the 
initiative, but don’t 
know much about it
I have some 
knowledge of the 
initiative and its 
activities.
I am well informed 
about the initiative
We have never referred 
clients to this resource 
in our program.  
We have occasionally 
referred clients to 
this resource in our 
program.
We sometimes refer 
clients to this 
resource in our 
program. 
We refer clients to 
this resource 
regularly in our 
program.
Not helpful Somewhat helpful Very helpful Unsure
18. Which of these statements best describes how your clients were prompted to get 
treatment?
oThey decided on their own to get treatment
oThey got treatment because someone else thought they should
oThey were ordered to get treatment
o Injury or near-death experience
oOverdose, or witnessing an overdose
oOther health issue
oOther (please specify) _____________
Prevention Efforts
For this section, we would like to hear your experiences and ideas related to current and future 
prevention efforts.  We would also like to know what needs your program has, and what needs 
your clients have, that DHHS may be able to fill in the future.  
Below is a list and description of prevention efforts DHHS is currently involved with.  Please 
rate your degree of knowledge about the program, and the degree to which you find the 
program helpful.  We would also like to know the degree to which you have utilized the 
information and resources provided by these programs and initiatives for yourself or for your 





Provides funding for medication and associated costs for clients with Opioid Use Disorder.  
Information at: http://dhhs.ne.gov/Pages/State-Opioid-Response.aspx
I have no knowledge of 
this initiative
I have heard of the 
initiative, but don’t 
know much about it
I have some knowledge 
of the initiative and its 
activities.
I am well informed 
about the initiative
We have never referred 
clients to this resource 
in our program.  
We have occasionally 
referred clients to 
this resource in our 
program.
We sometimes refer 
clients to this resource 
in our program. 
We refer clients to 
this resource 
regularly in our 
program.
Not helpful Somewhat helpful Very helpful Unsure
Increase Medication Assisted Treatment (MAT) workforce capacity
Provides education and support for DATA waiver certification of providers.  Information at: 
http://dhhs.ne.gov/Pages/State-Opioid-Response.aspx
I have no knowledge of 
this initiative
I have heard of the 
initiative, but don’t 
know much about it
I have some knowledge 
of the initiative and its 
activities.
I am well informed 
about the initiative
We have never utilized 
this resource in our 
program.  
We have occasionally 
utilized this resource 
in our program.
We sometimes utilize 
this resource in our 
program. 
We utilize this 
resource 
Regularly in our 
program.
Not helpful Somewhat helpful Very helpful Unsure
Naloxone Distribution
Distributes naloxone (Narcan®) to individuals at high risk of overdose through providers, law 
enforcement, first responders, and EMS.  Information at: http://dhhs.ne.gov/Pages/State-
Opioid-Response.aspx
I have no knowledge of 
this initiative
I have heard of the 
initiative, but don’t 
know much about it
I have some knowledge 
of the initiative and its 
activities.
I am well informed 
about the initiative
We have never utilized 
this resource in our 
program.  
We have occasionally 
utilized this resource 
in our program.
We sometimes utilize 
this resource in our 
program. 
We utilize this 
resource 
Regularly in our 
program.




(Targeted at non-users and general public)
Prescriber education □
PSA and media campaigns for general public □
Public education about medication assisted treatment (MAT) □
School-based substance use prevention programs—ELEMENTARY STUDENTS □
School-based substance use prevention programs—MIDDLE SCHOOL STUDENTS □
School-based substance use prevention programs—HIGH SCHOOL STUDENTS □
Secondary Prevention 
(targeted at early use, before serious complications)
Addiction screening for those presenting for early refills (to refer for treatment 
and services) □
Use of Prescription Drug Management Program before prescribing controlled 
substances □
Addiction screening at primary care facilities (similar to ways in which they might 
screen for mental health) □
Tertiary Prevention 




Mandatory counseling and services with buprenorphine or naltrexone 
administration (similar to methadone requirements) □
Increased access to 12-step programs □
Increased access to mental health treatment □
Increased access to and training on naloxone □
Education about safe injection practices (i.e. how to clean needles, how to use a 
“taster shot”) □
22. In your opinion, what prevention efforts are most helpful? (Select up to 3 in each category)
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23. Based on your experience, what populations are in need of additional substance abuse 






oWomen of child-bearing age
oEnglish Language Learners
oPersons in rural areas
oPersons in urban areas
oFamilies living in poverty
o Incarcerated individuals
oCurrent substance users
o Individuals with mental illness
o Individuals experiencing food insecurity






Training and Resources for Treatment Providers 
For this section, we would like to know about any needs you have for training or resources, 
both for yourself as a provider, and for your clients.  




25. Which of the below topics would be useful for future training for yourself or other staff at 
your facility?  (Select up to 5)
oMedication assisted treatment (methadone, buprenorphine, naltrexone)
oClient assessments (i.e. trauma screening tools, addiction screening tools, etc.)
oTrauma-informed care
oEvidenced-based treatments (i.e. EMDR, DBT, TF-CBT, etc.)
oTreatment for opioid addiction








oHuman growth and development
oMedical and psychosocial aspects of drug and alcohol use and addiction
oLGBT health issues




oOther addition (non-substance addiction)
oSuicide screening
oMedicaid, Medicare, and health insurance
oCompassion fatigue, stress, and burnout
oCultural competency
oEthics and boundaries
oWorking with homeless population
oAlternative pain management strategies
oOther (please specify) ___________




27. What additional resources do your clients need?  (Select up to 5)
oNaloxone kits
oCondom distribution
oFinancial assistance for medication assisted treatment (MAT)
oChildcare
oMAT prescriber
oFunding for rural area
oEducation about MAT
o Information on how to access treatment
oReduction in waiting lists and wait time
oFacilities that accommodate women with dependent children
oCommunity Outreach
oOther (please specify) ___________
28. What would you most like DHHS to know about your clients, and your work? 
(open-ended)
29. DHHS is committed to hearing directly from providers about needs and trends as we 
develop future programming.  Would you be willing to participate in a follow-up study on drug-
use behaviors?








Pain Relievers Heroin Fentanyl Methamphetamines Benzodiazepines 
Benzodiazepines 2 2 1 0 -
Methamphetamines 2 2 1 - 0
Opioids 0 0 0 1 1
Methadone Clinic Drug Pairings 
Note: No methadone provider indicated a drug pairing for alcohol, antidepressants, marijuana, 
hallucinogens, inhalants, or cocaine.  As such, they are not included in the below table as a drug 
pairing or primary drug.  Methadone providers indicated drug pairings for heroin, fentanyl, and 
prescription pain relievers as primary drugs, but not as drug pairings. They are included in the 
below table only as primary drugs.
Inpatient Facility Drug Pairings 
Note: No inpatient provider indicated inhalants as a drug pairing for the first table of primary 
drugs.  Therefore, it is not included in the table below.  No inpatient provider indicated inhalants, 
fentanyl, or benzodiazepines as a drug pairing for the second table of primary drugs.  Therefore, it 




Pain Relievers Heroin Fentanyl Methamphetamines Benzodiazepines 
Alcohol - 9 4 3 12 7
Benzodiazepines 2 1 0 1 0 -
Cocaine 1 1 1 1 3 1
Fentanyl 0 0 2 0 0
Hallucinogens 0 0 0 0 1 0
Heroin 0 1 - 4 0 0
Marijuana 7 4 2 2 12 4
Methamphetamines 11 4 3 1 - 1
Opioids 2 1 0 1 1 1
Prescription pain 
relievers 0 - 4 3 1 0
Primary Drugs (n=20)
Drug Pairings Antidepressants Marijuana Hallucinogens Inhalants Cocaine
Alcohol 1 10 2 3 7
Cocaine 1 1 2 1 -
Hallucinogens 0 0 - 1 1
Heroin 0 0 0 0 1
Marijuana 1 - 4 5 5
Methamphetamines 1 9 1 2 5
Opioids 0 1 0 0 1
Prescription pain relievers 0 0 0 1 0
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Appendix D: Treatment Provider Consent Form and Script
Thank you for taking the time to join our discussion about the opioid crisis in Nebraska.  This 
focus group is conducted through the Support and Training of the Evaluation of Programs 
(STEPs) which is housed in the University of Nebraska at Omaha.  STEPs has partnered with 
NDHHS to complete a needs assessment for the Drug Overdose Prevention Program.  The 
purpose of the DOP Drug Use Behaviors project is to equip DHHS with the information to 
develop effective drug use prevention plans.
The results will help DHHS to focus on the needs of treatment providers and ultimately to 
reduce overdoses in Nebraska.  The purpose of today’s discussion is to gain information about 
your experiences with clients, how the DHHS prevention campaign impacts you, and what you 
need to improve your work. 
There are no right or wrong answers to the questions I am about to ask.  Please feel free to 
share your point of view even if it differs from what others have said.  You may talk with one 
another during the group.  I am here to ask questions, listen, and make sure everyone has a 
chance to share.  Please respect each other and keep everything that is said in this group to stay 
in this group.  We will be recording the focus group because we do not want to miss any of your 
comments, but the transcripts will only be reviewed by the researchers on this project.  We will 
keep the things that you say confidential.  That means your name won’t be connected to what 
you said.  When we report the results of this assessment, names will not be used.  The only 
exception is if you share something that indicates that you, or someone else, is in danger. 
The STEPs team has already created a Promising Practices report for DHHS.  An executive 
summary of this report can be available to you if you wish.  Please leave us your email address 
and it will be emailed directly to you.  This report will also be available on the Drug Overdose 
Prevention website resources page soon (DHHS.ne.gov).
If you have any questions after this focus group is completed.  Please contact the STEPs office 
at:
STEPs
UNO Barbara Weitz Community Engagement Center






Treatment Provider Focus Group Script
Introduction.  Participants will be provided a hard copy of the consent form for their records.
Hello and welcome. 
Thank you for taking the time to join our discussion about the prevention and treatment 
of drug overdoses in Nebraska.  This focus group is conducted by the Support and Training of 
the Evaluation of Programs (STEPs) which is a program of the Grace Abbott School of Social 
Work at the University of Nebraska at Omaha.  
NE DHHS invited STEPs to complete a research study for the Drug Overdose Prevention 
Program.  The purpose of the DOP Drug-Use Behaviors project is to equip DHHS with 
information to develop effective drug-use prevention plans and provide any needed 
training and resources for treatment providers.  The results will help DHHS to focus on the 
needs of treatment providers and ultimately to reduce drug misuse, substance use disorder and 
overdoses in Nebraska.  
The purpose of today’s discussion is to gain information about your services and 
clients, to hear your thoughts on prevention, and to assess your training and other 
resource needs.
There are no right or wrong answers to the questions I am about to ask.  Please feel free 
to share your point of view even if it differs from what others have said.  This is a group format, 
and you are encouraged to talk with one another during the group.  I am here to ask questions, 
listen, and make sure everyone has a chance to share.  
We ask that everyone respect each other’s opinions and to keep everything said in this 
group here.  We will be recording the focus group because we do not want to miss any of your 
comments; the transcripts will only be reviewed by the researchers on this project.  We will 
keep what you say confidential.  The only exception is if you share something that indicates that 
you or someone else is in danger. 
The STEPs team has created a Promising Practices report for DHHS and an executive 
summary of this report can be available to you, if you wish.  Please leave us your email address, 
and it will be emailed directly to you.  This report will also be available on the Drug Overdose 
Prevention website resources page soon (DHHS.ne.gov/pdmp).
Does anyone have any questions before we begin?
Introductions:  What is your name, role, and how many years have you worked in this role?
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As you know, drug misuse, substance use disorder and overdoses are a problem 
nationally as well as here in Nebraska.  We are wanting to have a conversation about the 
therapeutic services provided in NE.  We are conducting a series of focus groups with inpatient 
providers in the Lincoln and Omaha area.  Your responses to these questions will help to 
determine the needs we have in our state which will provide guidance to DHHS regarding 
grants and programs.
We have a series of questions that are grouped by topic area.  We’d like for this to be a 
conversation.
Our first topic is generally about the services provided at your center and the clients you serve.   
2. What services are provided at your center?
• Are any of these services specifically for methamphetamine?  For opioids?
3. What drugs are most of your clients in treatment for?
• Approximately what percent of clients have opioids as their main issue (as compared to 
other drugs)? 
4. How is any of this different from a couple of years ago?
5.  What are the gaps in service you are seeing?  
Next, let’s talk about your current training, and your needs, if any, for additional training and 
other resources.
6. Talk to us about the type of training you’ve received about drug use.  When was the training 
(years)?
• Was it in person or online?
• Stand alone or as part of another training?
• Mandatory or optional?
• Annual or one time only?
• What did you like most about the training you received?
• What did you like least about the training you received?
• What further training would be useful for you as a provider?
• Tell me about the training provided by your current agency to all staff.
• What other resources do you need in providing quality treatment for clients?
• What role do you see DHHS having in providing training and other resources?
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This next set of questions is a closer look at the clients you serve.  This is all general 
information on things you have observed as a provider.  
7. How would you describe your typical client?
• Age, SES, race, geographics (are clients traveling large distances for treatment)
• Typical risk factors including trauma, ACE scores
• Typical protective factors such as family, community 
• How is this different from a couple of years ago?
8. What do you hear about how your clients started using drugs? (prompts: access, age, 
prescription or party)
• How and where did your clients access drugs?  Have you noticed changes in availability?
• How is this different from a couple of years ago?
9. What do you think could be done to keep young people from first starting to use drugs? 
10. For the clients you have seen that have relapsed, Under what circumstances does it seem 
clients relapse?
11. Based on what clients tell you, what do you think drives overdose? 
This next section is about prevention of drug overdoses. 
12. What are prevention efforts you are aware of in your community?
13. Is there anything that you think is working well to prevent drug overdoses?  Opiate misuse?
14. What prevention efforts do you think should be targeted for youth?  
• Literature shows that 70% of clients who reported a history of drug treatment, did not 
access treatment until about age 20, which is about 3 years after initiation of nonmedical 
prescription opioid use.
15. If you could design a prevention plan, what would you be sure to include?
16. Is there anything about this community that you think makes it more or less likely for 
people to use drugs?  Specifically opiates?  
17. What do you wish the public understood about drug use, misuse and use disorders?  About 
opioid use, misuse and use disorders?
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18. What do you wish policymakers understood about drug use, misuse and use disorders?  
About opioid use, misuse and use disorders?
This next set of questions is a closer look at the clients you serve. This is all general 
information on things you have observed as a provider.  
7. How would you describe your typical client?
• Age, SES, race, geographics (are clients traveling large distances for treatment)
• Typical risk factors including trauma, ACE scores
• Typical protective factors such as family, community 
• How is this different from a couple of years ago?
8. What do you hear about how your clients started using drugs? (prompts: access, age, 
prescription or party)
• How and where did your clients access drugs?  Have you noticed changes in availability?
• How is this different from a couple of years ago?
9. What do you think could be done to keep young people from first starting to use drugs? 
10. For the clients you have seen that have relapsed, Under what circumstances does it seem 
clients relapse?
11. Based on what clients tell you, what do you think drives overdose? 
This next section is about prevention of drug overdoses. 
12. What are prevention efforts you are aware of in your community?
13. Is there anything that you think is working well to prevent drug overdoses?  Opiate misuse?
14. What prevention efforts do you think should be targeted for youth?  
• Literature shows that 70% of clients who reported a history of drug treatment, did not 
access treatment until about age 20, which is about 3 years after initiation of nonmedical 
prescription opioid use.
15. If you could design a prevention plan, what would you be sure to include?
16. Is there anything about this community that you think makes it more or less likely for people 
to use drugs?  Specifically opiates?  
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17. What do you wish the public understood about drug use, misuse and use disorders?  About 
opioid use, misuse and use disorders?
18. What do you wish policymakers understood about drug use, misuse and use disorders?  
About opioid use, misuse and use disorders?
Closing
We have covered a lot of information today.  Is there anything else that you think would be 
helpful for DHHS to know or additional considerations you feel need to be addressed?
